

Index

- abstinence violation effect, 668–669
- abuse
 meaning of the term, 36
See also substance abuse, 43
- acamprosate, 100, 139, 244, 375, 635
- acetaldehyde
 aversive effects of, 201–202
- acetylcholine, 100, 103
- acetylcholine genes
 associations with SUDs, 200–201
- acetylcholine receptors, 105
 role in development of
 nicotine tolerance, 395–396
- Acompla, 316
- Adderall, 9, 486, 489, 493
 nonmedical use, 507–508
- addict
 use of the term, 36
- addiction
 biological basis of, 122–123
 compulsive behaviors, 10–11
 concurrent use of two or
 more drugs, 410–411
 definition, 10
 differences in vulnerability
 to, 13
 DSM-5 usage, 42
 essential features (American
 Society of Addiction
 Medicine), 71
 meaning of the term, 36
 physiological or
 psychological view of,
 10–11
 process addictions, 10–11
 revised diagnostic criteria,
 504–506
 significance of a withdrawal
 syndrome, 10–11
 stages and essential features,
 124–125
- vignette (“Sally Quits Using
 Cocaine ... Until She Starts
 Again”), 121–122
- vulnerability related to
 dopamine D2 receptor
 density, 133–134
- addiction medicine, 75
- Addiction Severity Index, 37
 for adolescents, 62
 for adults, 62
- addiction stages, 124–125
 stage 1 (reinforcing effects
 of addictive drugs),
 125–129
 stage 2 (shift from
 pleasurable to dysphoric
 effects), 130–134
 stage 3 (compulsive drug-
 seeking), 135–143
 stage 4 (lingering
 vulnerability to relapse),
 144–152
- addictive behavior
 nonbiological influences on,
 216
 progression of, 248–251
 variety of pathways into
 addiction, 217
- addictive lifestyle, 11–13, 529
 risks related opioid drug use,
 563
- addictive personality concept,
 270–271
- ADH1B* gene, 201
- Adolescent Drug Involvement
 Scale (ADIS), 57
- adolescent drug use, 287–298
 alcohol abuse, 291–292
 attitudes and expectations
 about drug use, 295
 cannabis as a “gateway
 substance”, 468–469
 cannabis use, 466–469
 childhood stress and,
 295–296
- conduct disorder risk factor,
 293
- early indicators of SUD,
 292–296
- hazards of, 290–292
- low socioeconomic status
 risk factor, 296
- Monitoring the Future
 survey, 287–288, 291
- neurobehavior disinhibition
 and, 293–294
- parenting practices and,
 295–296
- peer associations and
 influences, 294
- psychopathology risk factor,
 293
- reported levels of drug
 consumption, 287–288
- risk factors for SUD,
 289–290, 292–296
- adolescent smoking, 414–417
 consequences of, 415–416
 electronic cigarettes, 415
 prevalence of, 415
 risk factors for, 416–417
- adoption studies
 genetic influence on SUDs,
 170–172
- adrenal hormones
 stress response, 151
- adrenaline, 151
- adrenocorticotrophic hormone
 (ACTH), 150, 184, 185
- Adult Children of Alcoholics
 (ACOA), 310
- 2-AG, 100, 105
- age-related vulnerability to
 neurological damage,
 369–370
- agonist drug action, 106–108
- AIDS, 577
 association with intravenous
 drug use, 546
 emergence in the 1980s, 546

- alcohol
- adolescent alcohol abuse, 291–292
 - alcohol content of alcoholic beverages, 310
 - alcohol myopia, 320–321
 - anxiolytic effect, 320
 - as a drug, 36
 - behavioral effects, 318–330
 - binge drinking, 50, 322–323
 - bioavailability, 311–313
 - blackouts (amnesic episodes)
 - caused by, 324–326
 - calories in alcoholic beverages, 310
 - cognitive effects, 318–330
 - concurrent use with other addictive drugs, 333–336
 - context effects, 331–332
 - cultural attitudes about, 307
 - disinhibition of behavior, 320–321
 - dose-related effects, 319
 - effects at increasing blood alcohol concentration (BAC), 319
 - effects of combination with other drugs, 329–330
 - effects on amino acid neurotransmitters, 313–315
 - effects on dopamine function, 315
 - effects on endocannabinoids, 316
 - effects on endogenous opioids, 316
 - effects on GABA activity, 100
 - effects on GABA function, 313–315
 - effects on glutamate function, 313–315
 - effects on neurotransmitters and brain function, 313–317
 - effects on serotonin function, 315
 - effects on sexual activity, 321–322
 - enduring cognitive effects of “social” drinking, 326–327
 - expectancy effects, 331–333
 - factors affecting blood alcohol concentration (BAC), 311–313
 - hangover, 330
 - hormonal stress response, 317
 - impaired cognition and dangerous behavior, 323–324
 - lethal overdose, 329–330
 - low potency compared with other drugs, 311
 - low-risk levels of consumption, 50
 - memory impairment, 324–326
 - negative emotional effects, 327–328
 - neuroadaptation, 317
 - pharmacodynamics, 313–317
 - pharmacokinetics, 311–313
 - popularity of, 307
 - prevalence and levels of alcohol consumption, 308–309
 - prevalence of use and SUDs, 8–9
 - problematic alcohol use, 309–310
 - receptor binding, 108
 - rewarding effects, 319–322
 - suicide risk, 327–328
 - teratogenic effects, 372–374
 - tolerance, 319
 - undesirable and dangerous effects, 322–330
 - US government attempts to suppress consumption, 309
 - use of alcoholic beverages, 310–311
 - varied consequences of drinking, 318
 - vignette (“Selling the Proposal”), 306–307
 - withdrawal syndrome, 110, 317
 - alcohol dehydrogenase (ADH), 201–202
 - Alcohol Expectancy Questionnaire (AEQ), 236
 - alcohol metabolism
 - aversive effects of acetaldehyde, 201–202
 - enzymes involved in, 201–202
 - genes that control it, 201–202
 - Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), 57
 - alcohol use disorders
 - adoption studies, 170–172
 - advanced stage of alcohol addiction, 349–350
 - age-related vulnerability to neurological damage, 369–370
 - alcoholic dementia, 365
 - Babor classification system, 353–357
 - behavioral impairment, 364–365
 - binary classification systems, 353–357
 - brain damage related to, 364–370
 - brain injury types and locations, 365–366
 - cardiovascular disease associated with, 371
 - classification systems, 353–357
 - Cloninger classification system, 353–357
 - COGA study, 197–198
 - cognitive impairment, 364–365
 - comparison with nicotine addiction, 384–385
 - cultural influences and vulnerabilities for women, 359–360
 - delirium tremens stage of alcohol withdrawal, 363–364
 - development of, 346–352
 - differential heritability, 174
 - DSM-5 diagnostic criteria, 44–45
 - emotional and other costs of, 349–350
 - endophenotypes for, 196
 - fetal alcohol spectrum disorder, 372–374
 - gender differences in incidence, 357

- alcohol use disorders (*cont.*)
 gender-related risk factors, 359–360
 gender-specific differences, 358–359
 immune system compromise, 370–371
 in women, 357–361
 incidence of, 344–346
 Jellinek's gamma-delta classification system, 353
 Korsakoff's syndrome, 364–365, 370
 lifespan course of, 350–352
 liver disease (including cirrhosis), 371
 lower response to alcohol and SUD risk, 183–184
 malnutrition and, 369–374
 measuring severity, 343–344
 mechanisms of neurotoxicity, 366–369
 medical problems from chronic alcohol consumption, 362–374
 negative consequences expressed in popular culture, 341–342
 patterns and consequences for women, 361
 recovery from cognitive impairment, 370
 research on, 341–342
 risk factors for, 346–347
 special features in women, 357–361
 suicide risk, 350, 361
 thiamine deficiency and, 369–374
 transition from benign use into use disorder, 347–349
 treatment medications, 375–376
 twin studies, 173–174
 Type 2 alcoholism, 238
 types of, 353–357
 use of the terms *alcoholism* and *alcoholic*, 343
 variations among, 342–344
 viewed as a single disorder, 342–343
 vignette (“The AA Meeting”), 341
 Wernicke-Korsakoff syndrome, 364–365
 withdrawal syndrome, 362–364
 Alcohol Use Disorders Test (AUDIT), 57, 59
 alcoholic
 use of the term, 36, 343
 Alcoholics Anonymous (AA), 11, 22, 136, 244, 309, 325, 343, 627, 645–650, 675
 alcoholism as a single disorder, 343
 basic principles, 645–647
 beneficial features, 647–649
 evidence of effectiveness, 650
 founding and influence of, 74–75
 informal diagnosis of SUDs, 37
 mutual help approach, 628–629
 objections and limitations, 649–650
 risk factors for relapse, 149–150
 role of narcissism in addiction, 274–275
 spirituality of, 645–647
 terminology used by, 36
 twelve steps of, 646–647
 alcoholism
 use of the term, 343
 See also alcohol use disorders
 aldehyde dehydrogenase (ALDH), 201–202
ALDH2 gene, 202
 alleles, 192
 allostasis, 132–133
 alprazolam, 100, 108, 262, 603, 606, 612
 withdrawal syndrome, 114, 115
 Alzheimer's disease, 103, 365
 Ambien, 486, 613
 American Academy of Pain Medicine, 579
 American Cancer Society, 430
 American Lung Association, 430
 American Medical Association
 alcoholism as a disease, 75
 recognition of addiction medicine specialty, 75
 American Pain Society, 578
 American Psychiatric Association (APA), 9
 See also *Diagnostic and Statistical Manual of Mental Disorders* (DSM)
 American Psychological Association, 25
 American Society of Addiction Medicine, 478, 578
 essential features of addiction, 71
 amino acid neurotransmitters, 100
 effects of alcohol, 313–315
 amphetamine
 mechanism of action, 107
 d-amphetamine, 9
 amphetamine use
 acute effects, 496–503
 animal self-administration studies, 498–499
 armed forces, 488, 496–497
 behavioral effects, 496–498
 bioavailability, 493–494
 differences in individual responses, 501–502
 dosage effects, 496
 early twenty-first century, 492–493
 effects of injecting, 502–503
 effects on brain function, 494–496
 effects on neurotransmitters, 99, 494–496
 euphoric “rush” followed by aversive dysphoria, 502–503
 history of, 487–493
 incentive to escalate, 503
 narcolepsy treatment, 489
 nonmedical uses, 486
 performance-enhancing effects, 496–497
 pharmacodynamics, 494–496
 pharmacokinetics, 493–494
 physiological effects, 496–498
 prevalence of use and use disorders, 492–493
 routes of administration, 493
 sensitization to effects, 109
 stimulant effects, 487
 subjective effects, 499–500
 treatment for ADHD, 489
 twentieth century, 488–489

- vignette (“The Pharmacist Dispenses Drugs”), 486
 weight loss, 489
- amphetamine use disorders, 503–512
 addiction development and progression, 508–512
 amphetamine use binges, 509–510
 concurrent use of other addictive drugs, 509
 dangers of intravenous injection, 510–512
 development of tolerance, 509
 harm to organ systems and biological function, 524–525
 nonmedical use of pharmaceutical stimulants, 507–508
 prevalence of addiction among users, 504–506
 risk factors for problematic use, 506–507
 routes into addiction, 508–509
- amygdala, 126, 127, 134, 139, 150
 extended amygdala, 151
 significance of size (volume), 23, 186
- analgesia
 effects of opioid drugs, 554–555, 557–558
- anandamide, 100, 105, 316, 447, 448–449
- Anderson, Dwight, 74
- anecdotal accounts of drug addiction, 14–16
- angel dust.
 See phencyclidine
- animal models of addiction, 25–26
- animal studies
 genomic difference and SUDs, 204–208
 inbred mice and quantitative trait loci (QTLs), 205–206
 knockdown mouse strains, 206
 knockout (KO) mouse strains, 206–208
 mutant mice, 206–208
 selective breeding of experimental animals, 205
- transgenic (TG) mouse strains, 206–208
- ANKFN1* gene, 204
- Antabuse, 89, 375–376, 635
- antagonist drug action, 106–108
- antipsychotic medications
 effects of smoking tobacco, 410–412
- antisocial personality disorder, 12, 81, 177–178, 182, 201, 238, 259, 270, 293, 294, 348
 co-occurrence with borderline personality disorder, 274
 co-occurrence with SUDs, 53, 271–273
- anxiety disorders, 178–179
 co-occurrence with SUDs, 53–54, 264–267
 difficulty of nicotine withdrawal, 404
 drug treatment since 1900, 596–597
 prevalence of smoking in people with, 407–409
 self-medication, 264–267
 types of anxiolytic drugs, 595
 use of SSRI antidepressant drugs, 596
- anxiolytic drugs, 48, 100
 alcohol, 320
 misuse of, 597–598
 types of, 595
 withdrawal syndrome, 114
- Aricept, 103
- armed forces
 use of amphetamine, 488, 496–497
- associative learning, 218
- Ativan, 603
- attention-deficit hyperactivity disorder (ADHD), 116, 182, 199, 283, 293, 373, 521
 drug treatments, 489
 genetic factors, 193
- autoreceptors, 105
 inhibitory feedback function, 109
- availability of addictive drugs, 246
- aversive consequences of drug use, 226–228
- aversive effects of high drug doses, 134
- avoidant personality disorder, 275
- Babor, T.F.
 classification of alcohol use disorders, 353–357
- baclofen, 244
- Baker, Chet, 545
- Bandura, Albert, 232, 245
- barbiturates, 100, 262, 595, 596, 598–601
 acute effects, 600
 bioavailability, 599–600
 effects on brain function, 599
 misuse and use disorders, 600–601
 pharmacodynamics, 599
 pharmacokinetics, 599–600
 risk of fatal overdose, 600
 tolerance, 601
 treatment of use disorders, 617
 withdrawal syndrome, 601
- Baudelaire, Charles, 455
- Bechara, Antoine, 140
- Beck Depression Inventory, 528
- bed nucleus of the stria terminalis (BNST), 127, 150, 151
- Begleiter, Henri, 24, 181–182, 198
- behavior
 interaction with gene expression, 195–196
 modeling of, 245–246
- behavior and SUDs
 use of endophenotypes, 196–197
- behavioral genetics, 28
 complexity of, 191–193
- behavioral inhibition
 impairment in addiction, 139–143
- behavioral neuroscience, 28
- behavioral pharmacology, 25, 219, 249
- behavioral phenotypes, 192
- behavioral research (classic Skinnerian), 29
- behavioral sensitization, 136–137, 154
 long-term potentiation and, 154

- behavioral theory of SUD,
 218–232
 associative learning, 218
 aversive consequences of
 drug use, 226–228
 consequences of behavior,
 219
 consequences of drug use,
 218–228
 negative reinforcement,
 225–226
 positive reinforcement,
 219–225
 progression of SUD, 248–251
 reinforcement principle, 219
 role of learning in behavioral
 flexibility, 218–219
 stimulus control of SUD,
 228–232
 vignette (“The Power of an
 Immediate Reward”), 215
- behavioral tolerance, 110,
 115–116
- Belushi, John, 546
- Benowitz, N.L., 383, 395,
 396–397–399, 413, 421,
 426, 427, 430
- Benzedrine, 488
- benzodiazepine receptor
 agonists (BZRAs),
 596–597, 612–617
- abuse potential, 614–615
 adverse effects, 616–617
 bioavailability, 613–614
 effects on brain function,
 614
 pharmacodynamics, 614
 pharmacokinetics, 613–614
 withdrawal syndrome,
 615–616
- benzodiazepines, 9, 48, 100,
 262, 314, 333, 595,
 596–597, 601–612
- acute effects, 606–607
 anterograde amnesia, 605
 bioavailability, 605–606
 concurrent use with other
 addictive drugs, 609–611
 drug-facilitated sexual
 assault, 606–607
 effects on brain function,
 603–605
 misuse and use disorder,
 607–612
 pharmacodynamics, 603–605
- pharmacokinetics, 605–606
 treatment of use disorders,
 617
 types of, 602–603
 withdrawal syndrome,
 611–612
- Berridge, K.C., 220
- beta-endorphin, 100, 184
- bioavailability of a drug
 factors affecting, 111
- biological factors and SUDs,
 123
- addiction stage 1 (reinforcing
 effects of addictive drugs),
 125–129
- addiction stage 2 (shift from
 pleasurable to dysphoric
 effects), 130–134
- addiction stage 3
 (compulsive drug-seeking),
 135–143
- addiction stage 4 (lingering
 vulnerability to relapse),
 144–152
- aversive effects of high drug
 doses, 134
- biological basis of addiction,
 122–123
- brain disease theory of SUDs,
 123
- changes in synaptic
 microstructure, 156–157
- dysfunction of the brain’s
 “go” and “stop” systems,
 123–124
- effects on gene expression,
 155–156
- homeostatic changes to
 the hedonic set-point,
 131–134
- how addictive drugs alter
 brain function, 123–124
- long-term memory and risk
 of relapse, 153–154
- neurological basis of
 positive reinforcement and
 pleasure, 126–129
- neurological substrates of
 withdrawal syndromes,
 130–134
- reward circuitry in the brain,
 126–129
- role of the mesolimbic
 dopamine system,
 126–129
- sensitization, 136–139
- stages and essential
 features of addiction,
 124–125
- vignette (“Sally Quits Using
 Cocaine ... Until She Starts
 Again”), 121–122
- biopsychosocial approach to
 SUDs, 26–28, 216–218
- complex etiology of SUDs,
 298–299
- nicotine addiction/
 dependence, 390
- relationship to the disease
 concept of SUDs, 90
- risk factors for SUDs, 27–28
- bipolar disorder, 259
- co-occurrence with SUD, 178
- genetic factors, 193
- prevalence of smoking,
 409–410
- self-medication with
 addictive drugs, 262–263
- birth defects
 contribution of maternal
 drug use, 20
- blood alcohol concentration
 (BAC)
 factors affecting, 311–313
- blood-brain barrier, 112–113
- potential for development
 of vaccines against drug
 effects, 113
- Blum, Kenneth, 198, 199
- borderline personality
 disorder, 270, 271–272,
 294, 348
- co-occurrence with
 antisocial personality
 disorder, 274
- co-occurrence with SUDs,
 53, 273–274
- Botox, 107
- botulism toxin, 107
- brain
 magnetic resonance imaging
 (MRI), 23
- mesolimbic dopamine
 system, 97
- psychoactive drug
 interactions with
 neurotransmitters, 98–99
- brain damage
 related to alcohol use
 disorders, 364–370

- brain derived neurotrophic factor (BDNF)
 effects on neuronal structure, 156–157
- brain function and SUDs, 123
 addiction stage 1 (reinforcing effects of addictive drugs), 125–129
 addiction stage 2 (shift from pleasurable to dysphoric effects), 130–134
 addiction stage 3 (compulsive drug-seeking), 135–143
 addiction stage 4 (lingering vulnerability to relapse), 144–152
 aversive effects of high drug doses, 134
 biological basis of addiction, 122–123
 brain disease theory of SUDs, 123
 brain imaging, 185–190
 changes in synaptic microstructure, 156–157
 differences as cause or consequence of SUDs, 181
 dopamine D2 receptor density, 187–190
 dysfunction of the brain's "go" and "stop" systems, 123–124
 EEG abnormalities, 181–182
 effects on gene expression, 155–156
 genetically determined differences in brain function, 181–190
 greater response to psychological stress, 184–185
 homeostatic changes to the hedonic set-point, 131–134
 how addictive drugs alter brain function, 123–124
 impairment of the "stop-system" and "go-system", 139–143
 involvement of prefrontal cortical structures, 140–143
 long-term changes in brain function, 153–154
- long-term memory and risk of relapse, 153–154
 lower response to alcohol, 183–184
 magnetic resonance imaging (MRI) studies, 186
 neurological basis of positive reinforcement and pleasure, 126–129
 neurological substrates of withdrawal syndromes, 130–134
 nucleus accumbens, 126–129
 positron emission tomography (PET), 186–190
 research with family history positive (FHP) subjects, 181
 reward circuitry in the brain, 126–129
 role of the mesolimbic dopamine system, 126–129
 sensitization, 136–139
 stages and essential features of addiction, 124–125
 ventral tegmental area, 126–129
- brain imaging
 brain activity related to craving, 243–244
 genetic influence on SUDs, 185–190
 use in diagnosis of SUDs, 61
- brain structure and activity investigations, 22–24
- Brevital, 600
 brief intervention, 56, 635, 663
 Brown, Jackson, 486
 Buckley, William F., Jr., 286
 bulimia nervosa, 11
 buprenorphine, 13, 552, 553, 572, 585
 concurrent use with benzodiazepines, 609–610
 effect duration, 556
 management of opioid addiction, 587
 nonmedical use, 568
 partial agonist action, 108
 bupropion, 430–431, 534
 Burger's disease, 421
 Burroughs, William, 545, 558
- caffeine, 108, 487
 CAGE test, 57
 Campral, 100, 244, 375, 635
 cancer risk
 related to smoking, 421
 candidate-gene association studies, 198
 cannabidiol (CBD), 479
 cannabinoid receptors, 556
 discovery of, 447–448
 cannabinoids, 100–101, 129, 447
 illicit use of synthetic cannabinoids, 476–477
 medical use, 477–480
 cannabis, 99
 alternative names for, 439
 as a "gateway substance", 468–469
 bioavailability of THC, 445–446
 effects on brain function, 448–449
 endogenous cannabinoid system, 446–448–449
 forms of, 439–440
 hashish, 440
 high-potency strains, 439–440
 identification of THC, 446–447
 increase in potency over time, 443
 pharmacodynamics of THC, 448–449
 pharmacokinetics of THC, 445–446
 "skunk" cannabis, 439–440
See also tetrahydrocannabinol (THC)
Cannabis sativa varieties, 439
- cannabis use
 1960s to early twenty-first century, 441–443
 acute effects, 449–459
 addictive potential, 457, 460–461
 adolescents, 466–469
 aerosol and vapor delivery systems, 444
 alarmist stories and public health concerns, 441
 amotivational syndrome, 474–475
 analgesic effects, 451

- cannabis use (*cont.*)
 animal studies, 450–451
 appetite-increasing effect, 451
 behavioral effects, 452–453
 biotoxicity, 469–474
 challenges for researchers, 449–450
 cognitive effects, 452–453
 cognitive impairment, 470–474
 concurrent with cigarette smoking, 410–411
 decriminalisation in some US states, 443
 discovery of cannabinoid receptors, 447–448
 duration of effects, 445–446
 early and middle twentieth century, 441
 effects on complex information processing, 453
 effects on driving performance, 457–458
 effects on time perception, 453
 endogenous cannabinoids, 448–449
 executive function impairment, 459
 factors influencing drug effects, 449–450
 history of, 440–443
 immediate hazardous effects, 457–459
 introduction into the United States, 441
 legal status, 443
 legislation against, 441
 lessening of restrictions on, 443
 long-term consequences of heavy use, 469–476
 medical applications, 451, 477–480
 memory and learning impairment, 453
 methods of, 444
 modes of administration of THC, 445
 neurotoxicity, 470–474
 physiological effects, 451–452
 potential dangers of, 438
 prevalence of, 438, 444
 prevalence of use and SUDs, 8–9
 Reagan administration war on drugs, 442
 reasons for, 444
Reefer Madness (film, 1936), 441
 reward value, 454–457
 risk of fatal overdose, 451–452
 risk of psychosis, 475–476
 Shafer Commission (1972), 442
 subjective effects, 454–457
 THC in the brain and body, 445–449
 tolerance to the effects of THC, 449
 vignette (“Getting High and Getting Down to Work?”), 438
 cannabis use disorders, 459–466
 addiction, 459–460
 addictive potential of cannabis, 460–461
 addictive use of cannabis, 461–463
 DSM-5 criteria, 196
 entry into cannabis treatment programs, 460–461
 risk factors for cannabis dependence, 465–466
 symptoms of cannabis dependence, 461–463
 treatment of, 480
 withdrawal syndrome, 115, 464–465
 cardiovascular system disease associated with smoking, 421–422
 effects of alcohol consumption, 371
 carfentanil, 547
 Carr, David, 11, 510, 511
 Carroll, Kathleen, 5
 cathinone, 487
 causes of SUDs, 13–26
 differences in vulnerability to addiction, 13
 features which make identification difficult, 13–14
 Centers for Disease Control and Prevention (CDC), 387, 547
 guidelines for opioid prescription, 548
 ceramides, 368
 Cesamet, 478
 Chantix, 244, 383, 431, 534, 635
 chewing tobacco, 385, 420
 child abuse
 associated with stimulant drug use, 519–520
 childhood psychological dysregulation, 293
 childhood stress
 adolescent drug use and, 295–296
 chlordiazepoxide, 596, 602, 606
CHRM2 gene, 200
CHRNA5 gene
 implication in smoking behavior, 419
 chronic obstructive pulmonary disease (COPD)
 risk related to smoking, 422
 cigar smoking, 420
 cigarette smoking.
 See nicotine addiction/dependence; tobacco use
 Cigarette Withdrawal Scale, 402–403
 classical conditioning, 218
 classical learning theories, 218
 Clegg, Bill, 503
 clonazepam, 603
 Cloninger, Robert, 178
 classification of alcohol use disorders, 353–357
 Cloninger’s tri-dimensional theory of personality, 277–278
 Cocaine Anonymous, 645
 Cocaine Craving Questionnaire, 147
 Cocaine Selective Severity Assessment, 528
 cocaine use, 128
 acute effects, 496–503
 agonist effect on dopamine function, 107
 animal self-administration studies, 498–499
 behavioral effects, 496–498

- bioavailability, 493–494
 crack cocaine, 491
 development of a vaccine
 against its effects, 113
 differences in individual
 responses, 501–502
 dosage effects, 496
 early twenty-first century,
 492–493
 effects of injecting or
 inhaling, 502–503
 effects on brain function,
 494–496
 effects on neurotransmitters,
 99, 494–496
 euphoric “rush” followed
 by aversive dysphoria,
 502–503
 history of, 487–493
 incentive to escalate, 503
 pharmacodynamics, 494–496
 pharmacokinetics, 493–494
 physiological effects,
 496–498
 popular songs about, 486
 prevalence of cigarette
 smoking, 411
 prevalence of use and SUDs,
 8–9
 prevalence of use and use
 disorders, 492–493
 routes of administration, 493
 sensitization to drug effects,
 109
 stimulant effects, 487
 subjective effects, 499–500
 twentieth century, 488–492
 cocaine use disorders, 503–512
 addiction development and
 progression, 508–512
 antisocial behavior,
 519–520
 cocaine use binges, 509–510
 cognitive impairment,
 520–522
 concurrent use of other
 addictive drugs, 509
 consequences of heavy use,
 512–527
 craving, 529–530
 dangers of inhalation and
 intravenous injection,
 510–512
 development of tolerance,
 509
 effects on sexual activity,
 513–515
 experience of a crack
 cocaine addict, 511
 harm to organ systems
 and biological function,
 524–525
 neurotoxicity, 522–524
 prenatal exposure to cocaine,
 525–527
 prevalence of addiction
 among users, 504–506
 psychiatric syndromes
 related to heavy use,
 516–519
 risk factors for problematic
 use, 506–507
 routes into addiction,
 508–509
 stereotyped behavior,
 515–516
 toxic effects, 522–525
 treatment of addiction,
 533–535
 violence and child abuse
 associated with, 519–520
 withdrawal from heavy use,
 527–530
 codeine, 100, 551
 nonmedical use, 568
 cognition and SUD, 232–245
 craving, 238–245
 expectancy effects in SUD,
 235–238
 social learning theory, 232
 cognitive behavioral theory,
 232–233, 245, 261
 expectancy effects in SUD,
 235–238
 explanation of addiction,
 217
 progression of SUD, 248–251
 cognitive behavioral therapy
 (CBT), 234, 244, 533, 635,
 664–665
 cognitive control
 impairment in SUDs,
 139–143
 cognitive dissonance
 reduction of, 233–234
 cognitive mediation, 233–234
 influence of psychoactive
 drugs, 234–235
 Cohen, Sidney, 503
 Coleridge, Samuel Taylor, 558
 Collaborative Study on the
 Genetics of Alcoholism
 (COGA), 25, 49, 197–198,
 342
 Collins, Michael, 399, 400
 common factor model of SUD
 and psychiatric disorders,
 260, 268–269
 comorbidity
 co-occurring psychiatric
 disorders, 53–54
 value of longitudinal studies,
 19–20
 compensatory conditioning
 to drug-related stimuli,
 148–149
 compulsive behavior, 10–11,
 39–41
 compulsive drug-seeking,
 135–143
 craving, 136–139
 drivers of compulsive
 behavior, 135–136
 impaired cognitive control,
 139–143
 involvement of prefrontal
 cortical structures,
 140–143
 motivation for drugs,
 136–139
 sensitization, 136–139
 Concerta, 489, 493
 conditioned compensatory
 responses, 230–231
 opioid drugs, 566
 conditioned oppositional
 responses to drug-related
 stimuli, 148–149
 Conditioned Place Preference
 paradigm, 498
 conditioned responses to drug-
 related stimuli, 147–149,
 228–229
 conditioned responses to
 subliminal stimuli,
 231–232
 conditioned tolerance, 116
 opioid drugs, 561–562, 566
 conditioned withdrawal
 response, 149, 566–567
 conditioning
 classical conditioning, 218
 instrumental conditioning,
 218
 operant conditioning, 219

- conditioning (*cont.*)
 respondent conditioning, 218
 role in nicotine addiction/
 dependence, 389–390
- conduct disorder, 182, 200,
 201, 272, 294, 296, 373
 risk factor for adolescent
 drug use, 293
- consequences of SUDs, 13–26
 extent of use of psychoactive
 drugs, 5–6
 public health and safety
 issues, 13
 vignette (“Losing a Good
 Team Member”), 4–5
- context-dependent tolerance,
 230
- correlated liability model, 179
- correlational studies
 limitations of, 179–180
- corticotropin releasing factor
 (CRF), 134, 151, 152, 156,
 184, 317
- cortisol, 150, 151, 184, 185
- counseling, 657–662
- counterculture of the 1960s
 drug use, 545–546
- couples therapy, 667
- CPY2A6 gene
 implication in smoking
 behavior, 418–419
- CR OxyContin, 572
- crack cocaine, 491
- craving, 136–139, 187,
 238–245
 appetitive craving, 405
 aversive/relief-seeking
 craving, 405
 brain-imaging investigation,
 243–244
 cognitive demands of, 242
 conditioned responses to drug-
 related stimuli, 230–231
 conditioned responses
 to subliminal stimuli,
 231–232
 conditions that produce,
 240–242
 impact on working memory,
 242
 management and prevention
 of, 244
 measurement of, 239
 neurological basis of
 nicotine craving, 395–397
 neurological correlates, 24
 nicotine, 404–406
 nicotine dependence and,
 400–401
 relapse prediction and, 240
 relief craving, 239
 response to drug-related
 stimuli, 147
 reward craving, 239
 role in addiction, 239–240
 role of the insula in nicotine
 craving, 405–406
 stimulant drug withdrawal
 and, 529–530
- CREB (cAMP response element
 binding protein), 155–156
- cultural anthropology research,
 29
- cultural influences on SUD,
 246–248
 acceptance of tobacco use, 384
 availability of addictive
 drugs, 246
 cultural acceptance of
 intoxication, 246–247
 definition of culture, 246
 effects of prolonged national
 stress, 248
 interaction with other SUD
 risk factors, 247–248
 religious influence, 248
 use and attitudes among
 subcultures, 246
- Cymbalta, 99
- CYP2A6 enzyme
 metabolism of nicotine in
 the liver, 395
- Dalmane, 602, 606
- date rape drug (flunitrazepam,
 Rohypnol), 606–607
- defense mechanisms, 87–88,
 233–234
- delay discounting, 221–222
 influence on impulsive
 choice, 284–285
- delta FosB transcription factor,
 156, 157
- delta opioid receptors, 549
- dementia
 alcoholic dementia, 365
- Demerol, 551
- denial, 87–88, 234
- dependence.
 See substance dependence
- depression, 178–179, 194
 co-occurrence with SUD,
 53–54, 264–267
 difficulty of nicotine
 withdrawal, 404
 prevalence of smoking in
 people with, 407–409
 self-medication, 264–267
- designer drugs, 477
- developmental disorders
 contribution of maternal
 drug use, 20
- developmental research, 29
- diacetylmorphine.
 See heroin
- diagnosis of SUDs
 characteristics of individuals
 with SUDs, 53–54
 compulsive behavior, 39–41
 consideration of differences
 in personal circumstances,
 54
 co-occurring psychiatric
 disorders, 53–54
 cultural influences on, 51–52
 diagnostic instruments, 37
 diagnostic interview, 62–64
 difficulty of detecting and
 diagnosing in women, 54
 distinction between
 screening and diagnostic
 testing, 56
 distress or disability, 50
 DSM diagnostic criteria,
 9–10
 emotional relationship with
 the drug, 40–41
 essential features of SUDs,
 38–41
 establishing thresholds
 for identification of
 psychopathology, 49–50
 facilitating accurate self-
 reporting of substance
 use, 64
 false-positive evaluation
 (overdiagnosis), 52
 formal (professional)
 diagnosis, 36–37
 gender differences in SUDs,
 54
 harmful consequences of
 drug use, 38–39
 heterogeneity of SUDs,
 52–54

- high-functioning addicts, 51–52
- identifying an individual as an alcoholic or a drug addict, 35
- impaired control of behavior, 39–41
- impulsive behavior, 40
- informal diagnosis, 37–38
- language used for, 36
- objectivity, 51
- physiological withdrawal syndrome, 47–48
- routes of entry into diagnosis, 55
- screening tests, 37
- social influences on, 51–52
- stages of the diagnostic process, 55
- terminology, 36
- Three Cs test, 37–38
- use of endophenotypes, 196–197
- vignette (“Martin’s Diagnosis”), 33–35
- Diagnostic and Statistical Manual of Mental Disorders* (DSM), 41–49
- 3rd edition. *See* DSM-III
- 4th edition. *See* DSM-IV
- 5th edition. *See* DSM-5
- long-term studies and DSM revisions, 48–49
- relationship to the disease theory of SUDs, 49
- diagnostic instruments and procedures, 55–64
- brain imaging, 61
- diagnostic interview, 62–64
- facilitating accurate self-reporting of substance use, 64
- history of deviant or antisocial behavior, 60
- medical examination, 61
- personality inventory questionnaires, 60
- presence of risk factors for SUDs, 61–62
- psychiatric evaluation, 60
- routes of entry into diagnosis, 55
- screening tests for SUDs, 55–60
- stages of the diagnostic process, 55
- toxicology tests, 61
- use of additional information, 60–62
- diagnostic interview, 62–64
- diagnostic systems, 41
- categorical approach, 44
- dimensional approach, 44
- DSM system of the APA, 41–49
- ICD system of the WHO, 49
- relationship to the disease theory of SUDs, 49
- dialectical behavior therapy (DBT), 666–667
- diazepam, 262, 314, 596, 602, 605, 606, 608, 611
- protein-binding in the bloodstream, 115
- withdrawal syndrome, 114
- Dick, Danielle, 191
- DiClemente, Carlo, 233
- Dilaudid
- nonmedical use, 568
- disease concept of addiction, 217
- disease concept of SUDs
- acceptance by the medical profession, 75
- alternative to immorality or personal weakness explanations, 69
- basic tenets, 70–71
- behavioral manifestations of a disease, 71–73
- brain malfunction and, 123
- case for brain disease
- definition of SUDs, 71–73
- comparison with the biopsychosocial approach, 70
- consequences of acceptance, 78–79
- continuing cultural ambivalence regarding SUDs, 77
- discounting of nonbiological factors, 83–84
- early twenty-first century, 77–79
- essential features of addiction (American Society of Addiction Medicine), 71
- formation of NIAAA and NIDA, 76–77
- historical perspectives, 73–77
- immorality and sin view of drug use, 73–74
- in diagnostic systems, 49
- influence of Alcoholics Anonymous (AA), 74–75
- lessening of shame and guilt, 78–79
- limitations to the generality of the basic tenets, 84–90
- loss of control concept in SUDs, 88–90
- Minnesota Model of SUD treatment, 629
- neurological dysfunction and compulsive behavior, 82–83
- objections to, 79–84
- oversimplification of complex causes of SUDs, 83–84
- progression in addiction is not inevitable, 85–87
- reactive nature of some SUDs, 84–85
- relationship to the biopsychosocial explanation, 90
- rise in the number of treatment centers, 75
- role of nonbiological risk factors in SUDs, 90
- shift toward medicalization of addiction treatment, 78
- significance of denial and other defense mechanisms, 87–88
- skeptical views on, 77–78
- SUDs and addiction as primary disorders, 84–85
- SUDs without underlying brain disease, 80–82
- versions of disease theory, 70
- vignette (“A Good Person with a Bad Disease”), 68–69
- dishonesty
- in addictive lifestyle, 11–13
- disulfiram, 201, 375–376, 635

- DNA
 complexity of behavioral genetics, 191–193
 structure and function, 191–192
 DNA marker microarrays, 203
 Dolophine, 552, 585
 donepezil, 103
 dopamine, 99–100
 D2 receptor density and addiction, 133–134
 D2 receptor density and SUD risk, 187–190
DRD2 A1 allele association with SUDs, 198–199
DRD2 gene, 206
 effects of alcohol, 315
 genes associated with SUDs, 198–199
 homeostatic changes in the mesolimbic dopamine system, 131–134
 mesolimbic dopamine system, 97
 mesolimbic dopamine system and SUDs, 126–129
 positive reinforcement of drug effects, 126–129
 response to drugs, 24
 role in reinforcement, 99
 dopamine receptors, 105
 dorsolateral prefrontal cortex, 142
 dose-effect relationship
 aversive effects of high drug doses, 134
 dose effects of psychoactive drugs, 108
DRD2 A1
 association with SUDs, 198–199
DRD2 gene, 206
Drinking: A Love Story (Knapp), 11
 dronabinol, 478
 drug
 alcohol as a, 36
 scope of meaning, 36
 Drug Abuse Warning Network (DAWN), 329
 Drug Effects Questionnaire, 17, 221
 Drug Enforcement Administration, 479, 582
 drug manufacturing procedures to prevent misuse, 572
 drug-related stimuli
 learned associations, 24
 DSM-III, 49
 DSM-IV, 10
 diagnostic criteria for SUD, 9–10
 DSM diagnoses and long-term studies of SUD, 48–49
 incidence of nicotine addiction/dependence among smokers, 391
 measuring severity of alcohol use disorders, 343–344
 nomenclature of SUDs, 41–42
 revision of criteria for SUDs, 504
 substance abuse diagnosis, 42–43
 substance dependence diagnosis, 42–43
 terminology for severe SUD, 386
 DSM-5, 36, 41, 124
 cannabis use disorder, 196
 cluster B personality disorders, 271–272
 criteria for withdrawal from stimulant drug use, 527
 diagnostic criteria for alcohol use disorder, 44–45, 349
 diagnostic criteria for substance use disorder, 43–44, 45–47
 diagnostic criteria for SUD, 9–10
 diagnostic criterion of craving, 238
 different combinations of diagnostic criteria for SUD diagnoses, 52–53
 DSM diagnoses and long-term studies of SUD, 48–49
 incidence of nicotine addiction/dependence among smokers, 390–391
 measuring severity of alcohol use disorders, 343–344
 nicotine withdrawal symptoms, 399–400
 nomenclature of SUDs, 41–42
 personality disorders, 270
 terminology for severe SUD, 386
 variability of alcohol use disorders, 343
 duloxetine, 99
 dynorphins, 155, 549
 Earleywine, Mitch, 441
 eating disorders, 11
 ecstasy (drug).
 See MDMA
 electroencephalography (EEG), 24
 abnormal delta and theta oscillations, 182
 abnormalities associated with SUDs, 181–182
 P300 response, 182
 electronic cigarettes, 387, 415, 425–428
 cannabis delivery systems, 444
 use by adolescents, 415
 elimination of drugs from the body, 113–115
 emotional distress
 self-medication model, 261–262
 emotional relationship with the drug, 40–41
 endogenous cannabinoid receptors, 105
 endogenous cannabinoid system, 446–448
 endogenous cannabinoids, 99, 448–449
 effects of alcohol, 316
 endogenous opioid receptors, 105
 endogenous opioid system, 549–550, 555–556
 endogenous opioids
 definition, 542
 effects of alcohol, 170–176
 endophenotypes, 203
 association with genotypes, 198
 for alcohol use disorders, 196

- use in SUD diagnosis, 196–197
 endorphins, 102, 105, 129, 146–147, 185, 316, 549
 enkephalins, 105, 316, 549
 environment
 influence on drug effects, 116–117
 interaction with genetic influences in SUDs, 194–195, 208–209
 epidemiological surveys, 21–22
 epigenetics, 195
 effects of addictive drugs, 155–156
 eszopiclone, 613, 614, 616
 See also Z-drugs
 ethical issues in SUD research, 18
 etiology of SUDs, 298–299
 European Network of Genetic and Genomic Epidemiology (ENGAGE), 417
 executive function, 140
 exons, 195
 expectation
 effects in SUD, 235–238
 influence on drug effects, 116–117
 extended amygdala, 151
 Facebook, 632
 Fagerström Test for Nicotine Dependence (FTDN), 391–393
 family-associated risk of SUDs, 170
 family therapy, 667–668
 fat-sequestered drugs, 115
 fentanyl, 551–552
 introduction of, 543
 fentanyl use
 effect duration, 556
 escalation from prescribed opioids, 572–573
 estimates for the United States, 548
 features of illicit use, 574–578
 nonmedical use, 547, 568, 569
 onset of effects, 556
 pain management, 262
 prevalence of use and SUDs, 8–9
 routes of administration, 556
 vignette (“Anticipation”), 541
 fetal alcohol spectrum disorder, 372–374
 first-pass effect, 114
 Fletcher, Rafella, 575
 flunitrazepam, 606–607
 flurazepam, 602, 606
 Focalin, 489
 Foundation for a Smokefree America, 430
 Franklin, Benjamin, 307
 Freud, Sigmund, 87
 functional magnetic resonance imaging (fMRI) of the brain, 24
 GABA, 100
 effects of alcohol, 313–315
 GABA genes
 associations with SUDs, 199–200–201
 GABA receptors, 105
GABRA1 gene, 200
GABRA2 gene, 200, 201, 203
 gambling disorder, 11
 Garland, Judy, 601
 “gateway substance”
 cannabis as, 468–469
 Gautier, Théophile, 455
 gender differences in SUDs, 54
 gene–environment interaction, 195, 201–202
 gene expression
 CREB (cAMP response element binding protein) transcription factor, 155–156
 delta FosB transcription factor, 156
 effects of psychoactive drugs, 195–196
 epigenetic effects of addictive drugs, 155–156
 influence of addictive drugs, 155–156
 influence of metabotropic receptor activation, 155
 influences on, 195–196
 interaction with behavior, 195–196
 production of brain-derived neurotrophic factor (BDNF), 156–157
 generalized anxiety disorder
 smoking and, 408
 genes related to SUDs
 acetylcholine genes, 200–201
 candidate-gene association studies, 198
 COGA study, 197–198
 confounding effect of stratification, 197
 dopamine system and the *DRD2* gene, 198–199
 GABA genes, 199–201
 genes that control alcohol metabolism, 201–202
 identification of specific SUD-related genes, 197–204
 nicotine dependence genes, 202
 potential benefits of identifying, 197
 use disorders with illicit drugs, 202–203
 whole-genome association tests, 203–204
 genetic influence on SUDs, 170
 adoption studies, 170–172
 alcohol use disorders, 173–174
 brain imaging, 185–190
 complexity of behavioral genetics, 191–193
 co-occurrence of different SUDs, 175
 correlated liability model, 179
 differences in brain function, 181–190
 differential heritability of alcohol use disorders, 174
 difficulty of identifying specific genes, 191
 EEG abnormalities, 181–182
 epidemiological evidence, 170–176
 family-associated risk of SUDs, 170
 family patterns of SUD incidence, 168
 genomic differences and SUDs, 191–208

- genetic influence (*cont.*)
 greater response to
 psychological stress,
 184–185
 individual differences in
 vulnerability, 167–170
 initial drug use, 177–178
 interaction with
 environmental factors,
 208–209
 limitations of correlational
 studies, 179–180
 longitudinal studies,
 179–180
 lower response to alcohol,
 183–184
 nature of the biological
 predisposition, 176–208
 nicotine use and dependence,
 174
 personality factors, 177–180
 prospective studies, 179–180
 psychopathology, 177–180
 research approaches,
 168–170
 search for specific genetic
 factors, 174–175
 selective breeding of
 experimental animals,
 205
 stress-related activation of
 the HPA axis, 184–185
 transition to SUDs, 178–179
 twin studies, 172–175
 vignette (“Russell Cons
 His Mother – Again”),
 166–167
- genetic predisposition, 20
 common factor model,
 268–269
 smoking and nicotine
 dependence, 417–419
 genetic vulnerability to SUDs
 investigations, 25
 genomic differences and SUDs,
 191–208
 animal studies, 204–208
 complex genetic basis of
 SUDs, 191–193
 endophenotypes, 196–197
 identification of specific
 SUD-related genes,
 197–204
 influences on gene
 expression, 195–196
- interaction with
 environmental influences,
 194–195, 195–196
 involvement of multiple
 genes, 193–194
 odds ratios for risk factors,
 193
 genotypes, 192, 195
 association with
 endophenotypes, 198
 glutamate, 100, 129
 effects of alcohol, 313–315
 glutamate receptors, 105
 glutamate toxicity, 368–369
 glutamic acid.
 See glutamate
 Gordon, Barbara, 607
 government
 attempts to reduce smoking
 in the United States,
 385–386
 group therapy, 659–660
- Haggard, Howard, 74
 Halcion, 603
 haldol, 108
 HALT (hunger, anger,
 loneliness, fatigue [tired])
 risk factors for relapse,
 149–150
 Hammer, Rachel, 82
 Harrison Narcotics Act (1914),
 544
 hashish, 440
 Hazelden Foundation, 629
 health-care professionals
 drug misuse and addiction,
 582–584
 Heaviness of Smoking Index
 (HIS), 392
 hedonic set-point
 homeostatic responses to
 drugs, 131–134
 influence of stress responses
 to dysphoric drug effects,
 134
 shift caused by opioid drug
 use, 564
 shift caused by stimulant
 drugs, 529
 heroin, 100, 551
 introduction of, 543
 heroin overdose
 action of naloxone, 553
 heroin use
 American military personnel
 in the Vietnam conflict,
 545
 concurrent use of
 benzodiazepines, 609
 conditioned withdrawal
 response, 566–567
 escalation from prescribed
 opioids, 572–573
 estimates for the United
 States, 548
 history and features of,
 573–578
 onset of effects, 556
 pain management, 262
 passage through the blood-
 brain barrier, 112–113
 prevalence of cigarette
 smoking, 411
 prevalence of use and SUDs,
 8–9
 receptors activated by, 104
 vignette (“Anticipation”), 541
 high-functioning addicts,
 51–52
 Hill, Shirley, 23, 186
 histrionic personality disorder,
 271, 274
 HIV infection, 521, 534
 intravenous drug use and,
 577
 risk from intravenous drug
 use, 546
 HIV-1 infection, 366
 Hoffman, Phillip Seymour,
 576
 homeostatic processes in the
 CNS, 109
 homeostatic responses to drugs
 changes in the hedonic set-
 point, 131–134
 hormones
 neurotransmitters, 100
 responses to stress, 151
 Hughes, John, 399
 human genome project, 192
 Huntington’s disease, 193
 hydrocodone, 9, 547, 551, 568
 nonmedical use, 568
 hydromorphone
 nonmedical use, 568
 hyperalgesia
 induced by opioid drugs, 563
 hypothalamic-pituitary axis,
 134

- hypothalamic-pituitary-adrenal (HPA) axis
 level of activation in response to stress, 184–185
 role in addiction relapse, 151–152
- ice (form of methamphetamine), 491–492
- identification of SUDs, 9–10
- illicit drugs
 identifying genes related to SUDs, 202–203
- Immovane, 613
- immune system
 effects of alcohol use disorders, 370–371
- impulsive behavior, 40
- impulsivity and SUD, 280–281–286
 aspects of impulsivity, 281–282
 behavioral tests of impulse control, 284
 delay discounting and impulsive choice, 284–285
 impulsive behavior as a choice, 286
 measurement of impulsivity, 282
 neurological factors and impulse-control deficit, 283
 positive aspects of impulsive behavior, 286
 self-control in hiding problematic drug use, 286
- incentive sensitization, 137–138, 147, 231
- incentive value of a stimulus, 137, 149
- Infant Development, Environment and Lifestyle study (IDEAL), 526
- inhalation route of entry of drugs, 112
- initial drug use
 influence of personality factors, 177–178
 influence of psychopathology, 177–178
- injection (intravenous) route of entry for drugs, 112
- injection (muscle or beneath skin) route of entry for drugs, 112
- insomnia
 benzodiazepine receptor agonists (BZRAs), 612–617
 drug treatment since 1900, 596–597
 types of sleep-promoting drugs, 595
 Z drugs, 612–617
- instrumental conditioning, 218
- insula
 role in nicotine craving, 405–406
- insular cortex, 243
- insulin resistance
 related to smoking, 422
- International Classification of Diseases and Related Health Problems (ICD), 49
- nicotine withdrawal symptoms, 401
- relationship to the disease theory of SUDs, 49
- International HapMap project, 203
- Internet
 information on SUDs and treatment, 632–633
- intra-gastric route of entry for drugs, 112
- intravenous injection of drugs, 112
- introns, 195
- inverse agonist drug action, 108
- ionotropic receptors, 155
- Iowa Gambling Task, 284
- Iversen, Leslie, 441
- Jacobs, Andrew, 513
- Jellinek, E.M., 74, 75, 83, 86, 89, 325
 gamma-delta classification of alcohol use disorders, 353
 Jellinek chart of the course of alcoholism, 350
- Joplin, Janis, 546
- journals that report SUD research, 18
- judgment
 cognitive mediation, 233–234
 influence of psychoactive drugs, 234–235
- JWH-018 (synthetic cannabinoid), 477
- K2 (synthetic cannabinoid), 477
- Kalivas, P.W., 220
- kappa endorphin receptors, 104
- kappa opioid receptors, 549, 550
- Keller, Mark, 83
- Keyes, Katherine, 22
- kidneys
 role in drug elimination from the body, 113
- Klonopin, 603
- Knapp, Caroline, 11, 347, 349
- Koob, George, 124, 131–134, 135–136, 139, 220, 230, 396–397
- Korsakoff's syndrome, 364–365, 370
- Kreek, Mary Jane, 178
- Kristofferson, Kris, 341
- Lashley, Karl, 153
- Lawford, Christopher, 15
- Le Moal, Michel, 124, 131–134, 396–397
- learned associations
 drug-related stimuli, 24
- learning
 expectancy effects in SUD, 235–238
 role in behavioral flexibility, 218–219
- Lewis, Marc, 82–83
- Lexington prison/hospital opioid drug studies, 14–15
- Librium, 596, 602, 606
- life experience and SUDs
 interaction with genetic influences, 194–195
- LifeRing Secular Recovery, 651
- lifestyle
 addictive lifestyle, 11–13
- limbic-system reward circuitry, 556
- lipid neurotransmitters, 100–101

- liver
 disease caused by alcohol, 371
 first-pass effect, 114
 role in drug elimination from the body, 113–114
 role in metabolic tolerance, 113–114
- long-term memory
 risk of SUD relapse and, 153–154
- long-term potentiation, 154
- longitudinal studies, 19–20
- lorazepam, 603
- loss of control concept in SUDs, 88–90
- LSD, 104, 545
- Ludlow, Fitz Hugh, 455, 457
- Luminal, 599
- Lunesta, 613
- MAC test, 60
- Macy, Beth, 587–588
- magnetic resonance imaging (MRI)
 brain studies, 186
 use in diagnosis of SUDs, 61
- marijuana. *See* cannabis
- Marinol, 478
- Matching Familiar Figures Test, 284
- Matrix Model for SUD
 treatment, 533–534
- McCabe, Sean, 569–570
- McCrae and Costa five-factor theory of personality, 277
- MDMA, 487, 530–533
 addiction, 532
 addictive potential, 531–532
 aversive effects, 532
 chemical formula, 530
 cognitive deficits associated with, 532–533
 development of tolerance, 531–532
 early therapeutic use, 530
 effects in the brain, 531
 effects of prenatal exposure, 533
 effects on neurotransmitters, 99, 531
 history of use, 530–531
 hyperthermia risk, 532
- mechanism of action, 107
- memory impairment, 532–533
- neurotoxicity, 532
- potential for further therapeutic use, 531
- prevalence of use, 531
- Schedule I classification in the United States, 531
- sensitivity of women to, 530
- street names for, 530
- subjective effects, 530
- use at “raves” and as a club drug, 530–531
- mechanism of action of drugs, 106–108
- medical examination
 diagnostic use, 61
- medical professionals
 drug misuse and addiction, 582–584
- medical use
 cannabidiol (CBD), 479
 cannabis and cannabinoids, 477–480
 opioid drugs, 541
 use and misuse of prescription opioids, 546
- memory
 long-term memory effects of SUDs, 153–154
 working memory impact of craving, 242
- Mendelian inheritance, 193
- meperidine, 551
- Mercer, Robert, 612
- mesolimbic dopamine system, 97
 homeostatic changes to the hedonic set-point, 131–134
 role in development of SUDs, 126–129
- metabolic tolerance, 110, 113–114
- metabotropic receptors
 influence on gene expression, 155
- methadone, 13, 552, 585
 concurrent use with benzodiazepines, 609, 610
 effect duration, 556
 management of opioid addiction, 586
 nonmedical use, 568
- methamphetamine use
 bioavailability, 493–494
 dosage effects, 496
 early twenty-first century, 492–493
 effects of injecting or inhaling, 502–503
 effects on brain function, 494–496
 effects on neurotransmitters, 494–496
 euphoric “rush” followed by aversive dysphoria, 502–503
 history of, 487–493
 “ice” form of the drug, 491–492
 incentives to escalate, 503
 pharmacodynamics, 494–496
 pharmacokinetics, 493–494
 prevalence of use and SUDs, 8–9
 prevalence of use and use disorders, 492–493
 routes of administration, 493
 stimulant effects, 487
 subjective effects, 499–500
 vignette (“The pharmacist dispenses drugs”), 486
See also MDMA
- methamphetamine use disorders, 503–512
 addiction development and progression, 508–512
 antisocial behavior, 519–520
 cognitive impairment, 520–522
 concurrent use of other addictive drugs, 509
 consequences of heavy use, 512–527
 craving, 529–530
 dangers of inhalation and intravenous injection, 510–512
 development of tolerance, 509
 effects on sexual activity, 513–515
 harm to organ systems and biological function, 524–525
 meth mouth, 524–525

- methamphetamine use
 binges, 509–510
- methamphetamine use in the
 urban gay community,
 513
- neurotoxicity, 522–524
- prenatal exposure to
 methamphetamine,
 525–527
- prevalence of addiction
 among users, 504–506
- psychiatric syndromes
 related to heavy use,
 516–519
- risk factors for problematic
 use, 506–507
- routes into addiction,
 508–509
- stereotyped behavior,
 515–516
- toxic effects, 522–525
- treatment of addiction,
 533–535
- violence and child abuse
 associated with, 519–520
- withdrawal from heavy use,
 527–530
- Methamphetamine Withdrawal
 Questionnaire, 528
- Methland* (Reding), 516–517,
 519–520
- methohexital, 600
- methylphenidate, 9, 128, 487,
 493, 496, 498, 534
 nonmedical use, 507–508
 treatment for ADHD, 489
- Michigan Alcoholism
 Screening Test (MAST), 57
- midazolam, 603
- Miller, William, 5
- mindfulness training, 666
- Minnesota Model of SUD
 treatment, 629
- Minnesota Multiphasic
 Personality Inventory
 (MMPI), 60
- Minnesota Twin Family Study,
 177
- modafinil, 487, 489, 534
- modeling of behavior, 245–246
- Moderation Management, 651,
 652
- molly (drug). *See* MDMA
- Moments of Clarity* (Lawford), 15
- Monitoring the Future survey,
 21, 287–288, 291, 466
- monoamine neurotransmitters,
 99–100, 102
- monoamine oxidase (MAO)
 levels in tobacco smokers, 397
- monoamine-oxidase inhibitors,
 99
- Monroe, Marilyn, 601
- mood disorders, 178–179
 role of serotonin, 99
- morphine, 99, 100, 262, 551
 action of naloxone on, 553
 formulations to prevent
 misuse, 572
 half-life, 556
 introduction of, 543
 nonmedical use, 568
 passage through the blood-
 brain barrier, 112–113
 receptor binding, 107, 108
 receptors activated by, 104
- Morrison, Jim, 576
- Mothers Against Drunk Driving
 (MADD), 310
- motivation
 amotivational syndrome and
 cannabis use, 474–475
 motivation for drugs, 136–139
 motivational interviewing, 635,
 662
- mu endorphin receptors, 104
- mu opioid receptors, 549, 550,
 553–554, 555–556
- mucous membranes
 route of entry for drugs, 112
- Multidimensional Personality
 Questionnaire (MPQ),
 278–279
- multivariate statistical analysis,
 20, 22
- mutual-assistance groups,
 644–652
- nabilone, 478
- Nahas, Gabriel, 442
- naloxone, 552
 opioid addiction treatment,
 588
 treatment of drug overdose,
 553–554
- naltrexone, 100, 316, 375, 552,
 635
 effect duration, 556
 formulations, 556
 opioid addiction treatment,
 588
 use in opioid formulations to
 prevent misuse, 572
- Narcan, 552, 588
- narcissistic personality
 disorder, 270, 271,
 274–275
- narcolepsy
 amphetamine treatment, 489
- narcotic
 definitions, 542
- Narcotics Anonymous (NA), 11,
 22, 244, 629, 645
 informal diagnosis of SUDs,
 37
 terminology used by, 36
- Narcotics Control Act (1956),
 545
- National Cancer Institute, 388
- National Comorbidity Survey,
 22, 262
- National Council on
 Alcoholism, 76
- National Epidemiological
 Survey on Alcohol and
 Related Conditions
 (NESARC), 21, 22, 41,
 43, 86, 262, 264–267,
 272–273, 335, 336, 342,
 344, 345–346, 347, 351,
 355, 357, 391, 608
- National Health Interview
 Survey, 403
- National Institute on Alcohol
 Abuse and Alcoholism
 (NIAAA), 21, 50, 86, 309,
 343, 345, 632
 broadening scope of, 78
 formation of, 76–77
- National Institute on Drug
 Abuse (NIDA), 21, 287,
 388, 478, 479, 547, 632
 formation of, 76–77
 scope of, 78
- National Institutes of Health, 76
- National Institutes of Mental
 Health, 76
- National Survey on Drug Use
 and Health (NSDUH), 6,
 8–9, 21, 258, 262, 291,
 309, 342, 345, 390, 444,
 461, 531, 547–548, 626

- Nauta, Walle, 140
 negative emotionality and
 SUD, 280–281
 negative reinforcement, 125,
 225–226
 effects of opioid drugs, 558
 Nembatal, 599
 NEO Personality Inventory
 (NEO-PI), 277, 279
 neonatal abstinence syndrome,
 584–585
 neuroadaptation
 development of drug
 tolerance, 109–110
 neurobehavior disinhibition
 adolescent drug use risk
 factor, 293–294
 neuroimaging, 22–24
 use in diagnosis of SUDs, 61
 neurological substrates of acute
 and protracted withdrawal
 syndromes, 130–134
 neurons
 functions of, 97
 neurotransmitter binding
 with postsynaptic
 receptors, 101
 neurotransmitter
 inactivation, 101–102
 neurotransmitter release into
 the synapse, 101
 neurotransmitter removal
 from the synapse, 102
 neurotransmitter reuptake at
 the synapse, 102
 neurotransmitter synthesis,
 101
 receptor binding of
 neurotransmitters, 103
 structural effects of BDNF,
 156–157
 synaptic plasticity, 157
 synaptic structural changes
 caused by addictive drugs,
 156–157
 synaptic transmission,
 101–103
 neuropeptide Y (NP Y), 317
 neurotoxicity
 effects of stimulant drugs,
 522–524
 neurotransmitters
 acetylcholine, 100
 amino acid neurotransmitters,
 100
 binding to receptors, 103
 binding with postsynaptic
 receptors, 101
 cannabinoids, 100–101
 diversity of neurotransmitter
 functions, 103
 dopamine, 99–100
 drug influence on
 availability in the synapse,
 107
 effects of connecting with
 receptors, 97
 effects of MDMA, 531
 effects of nicotine, 395–397
 effects of stimulant drugs,
 494–496
 functions in behavior and
 cognition, 103
 GABA, 100
 glutamate, 100
 identification of, 98–99
 inactivation, 101–102
 interactions with
 psychoactive drugs, 98–99
 lipid neurotransmitters,
 100–101
 mechanisms of drug action,
 106–108
 monoamine class, 99–100
 noradrenaline, 99–100
 opioid neuropeptide
 neurotransmitters, 100
 psychoactive hormones, 100
 receptor types and subtypes,
 105
 release into the synapse,
 101
 removal from the synapse,
 102
 reuptake at the synapse, 102
 serotonin, 99–100
 synaptic transmission,
 101–103
 synthesis in neurons, 101
 Newlove, Donald, 352
 nicotine, 100
 addictive potential, 422–425
 bioavailability, 394–395
 cognitive effects, 398–399
 content of cigarettes,
 394–395
 CYP2A6 enzyme metabolism
 in the liver, 395
 effects on brain function,
 395–397
 effects on neurotransmitters,
 395–397
 effects on nonsmokers, 398
 effects on smokers and
 nonsmokers, 394
 electronic delivery systems,
 425–428
 half-life in the body, 395
 inhalers and nasal spray, 431
 insecticidal property, 394
 modes of access into the
 body, 394
 neurological basis of
 craving, 395–397
 pharmacodynamics, 395–397
 pharmacokinetics, 394–395
 physiological effects, 398
 recognition of its addictive
 potential, 51
 role of acetylcholine
 receptors in development
 of tolerance, 395–396
 stimulant effect, 487
 toxic effects of low doses,
 394
 toxicity of, 394
 transdermal patches, 398
 See also tobacco use
 nicotine addiction/dependence
 appetitive craving, 405
 approaches to treating,
 428–430
 aversive/relief-seeking
 craving, 405
 biopsychosocial view, 390
 cancer risks, 421
 comparison with alcohol use
 disorders, 384–385
 concurrent use of other
 addictive drugs, 410–411
 consequences of adolescent
 smoking, 415–416
 co-occurrence with
 psychiatric disorders,
 263–264
 definitions of addiction and
 dependence, 386
 determining the incidence
 among smokers, 390–394
 difficulty of stopping
 smoking, 403
 difficulty of stopping
 smoking with co-
 occurring psychiatric
 disorders, 406–407

- DSM assessment of
 incidence among smokers,
 390–391
- electronic cigarettes,
 425–428
- Fagerström Test for Nicotine
 Dependence (FTDN),
 391–393
- genes related to, 202
- genetic predisposition,
 417–419
- Heaviness of Smoking Index
 (HIS), 392
- hormonal factors in women,
 413
- lifestyle effects, 12
- light smokers (“chippers”),
 390
- mechanisms of toxicity, 421
- medications to help smoking
 cessation, 430–431
- NESARC study, 391
- Nicotine Dependence
 Syndrome Scale (NDSS),
 393
- nicotine metabolism and
CPY2A6 gene alleles,
 418–419
- nicotine substitution therapy,
 392
- NSDUH 2017 survey, 390
- personality traits and,
 411–412
- premature deaths caused by,
 420
- promotion by reinforcement,
 388–389
- reward value of nicotine,
 423–424
- risk factors for, 383
- role of *CHRNA5* gene alleles,
 419
- role of conditioning,
 389–390
- role of orexin, 406
- stopping smoking, 428–431
- synergistic toxic risk, 422
- terminology for severe SUD,
 386
- Three Cs criteria for SUDs,
 390–391
- treatment programs,
 428–430
- twelve-step programs and,
 429–430
- twin studies on use and
 dependence, 174
- vignette (“Thinking about
 Stopping Smoking”),
 382–383
- weight gain on stopping
 smoking, 413
- Wisconsin Inventory of
 Smoking Dependence
 Motives, 393–394
- withdrawal relief and,
 401–404
- women’s lower success
 in stopping smoking,
 412–413
- See also* tobacco use
- Nicotine Anonymous, 383,
 429–430
- Nicotine Dependence Syndrome
 Scale (NDSS), 393
- nicotine replacement therapy
 (NRT), 413, 421, 431
- nicotine withdrawal syndrome,
 174, 399–406
- animal models, 401
- Cigarette Withdrawal Scale,
 402–403
- craving, 400–401, 404–406
- effects of anxiety or
 depressive disorders, 404
- intensity in individuals with
 psychiatric disorders,
 406–407
- irritability and anxiety
 symptoms, 399–400
- motivation for continued
 abstinence, 401–404
- neurological basis, 395–397
- particular effects in women,
 412–413
- time course of symptoms,
 399–400
- tolerance for distress, 404
- withdrawal relief and
 dependence, 401–404
- nicotinic acetylcholine
 receptors, 395–396
- Niebuhr, Reinhold, 646
- Night of the Gun* (Carr), 11
- Nixon, Richard, 442
- nomenclature of SUDs
 DSM system, 41–42
- nonabstinent remission and
 recovery, 669–672
- nonbiological factors
 influence on addictive
 behavior, 216
- nongenetic factors
 influence on SUD risk,
 194–195
- noradrenaline, 99–100, 129,
 151
- role in relapse to drug use,
 99
- noradrenaline receptors, 105
- nucleus accumbens, 151, 156,
 195, 555
- role in SUDs, 126–129
- obesity
 use of amphetamine for
 weight loss, 489
- odds ratios for risk factors, 193
- Office on Smoking and Health,
 388
- ondansetron, 356
- operant conditioning, 219
- opiate
 definition, 542
- opioid
 definition, 542
- opioid addiction
 buprenorphine (partial
 agonist) treatment, 587
- management via drug
 treatment, 585–588
- medical management of, 13
- methadone maintenance,
 586
- resistance to provision
 of medication-assisted
 treatment (MAT), 587–588
- treatment with opioid
 antagonists, 588
- opioid analgesic drugs, 48
- prevalence of use and SUDs,
 8–9
- opioid drugs
 agonists, 550
- analgesia, 100, 554–555,
 557–558
- antagonists, 550
- aversive side effects, 560
- behavioral effects, 557–560
- bioavailability, 556
- conditioned compensatory
 response, 566
- conditioned tolerance,
 561–562, 566

- opioid drugs (*cont.*)
 conditioned withdrawal response, 566–567
 consequence of long-term use, 560–564
 development of tolerance, 561–562
 effects on brain function, 553–556
 endogenous opioid system, 549–550
 euphoria caused by, 558–560
 hyperalgesia induced by, 563
 interaction with the endogenous opioid system, 555–556
 manufacturing procedures to prevent misuse, 572
 medical use, 541
 mixed agonist-antagonist agents, 550
 negative reinforcement effects, 558
 opioid receptors, 549
 partial agonists, 550
 pharmacodynamics, 553–556
 pharmacokinetics, 556
 physiological effects, 557–560
 positive reinforcement, 558–560
 positive reinforcement mechanisms, 555–556
 protracted withdrawal syndrome, 563–564
 receptors activated by, 104
 risks related to the addictive lifestyle, 563
 routes of administration, 556
 subjective effects, 557–560
 terminology, 542
 variation in effect duration, 556
 withdrawal syndrome, 562–563–564
- opioid misuse and use disorders, 564–585
 behaviors suggestive of addiction, 579–580
 dependence and addiction in chronic-pain patients, 578–582
 dependence in the absence of a use disorder, 565
 distinguishing between dependence and addiction, 578–579
 drug manufacturing procedures to prevent misuse, 572
 fentanyl use, 574–578
 four types of, 567–584
 general features of, 564–567
 heroin use, 573–578
 increasing rates of, 541–542
 misuse and addiction by medical professionals, 582–584
 misuse of pharmaceutical opioids, 567–573
 neonatal abstinence syndrome, 584–585
 pseudoaddiction, 578, 579–580
 vignette (Anticipation), 541
 withdrawal syndrome in addicts, 565–567
- opioid neuropeptide neurotransmitters, 100
- opioid peptide neurotransmitters, 99, 549
- opioid receptors, 549
 delta opioid receptors, 549
 kappa opioid receptors, 549, 550
 mu opioid receptors, 549, 550, 553–554, 555–556
- Opioid Risk Tool, 581
- opioid use and misuse
 AIDS and intravenous drug use, 546
 CDC guidelines for opioid prescription, 548
 history of, 542–548
 opioid misuse “epidemic” in the United States, 546–548
 prescription opioids, 546
 twentieth century, 543–546
 twenty-first century, 546–548
 Vietnam conflict, 545
- opium, 542–543
- opium poppy (*Papaver somniferum*), 542
- oppositional defiant disorder, 296
- orbitofrontal cortex, 142
- orexin
 role in nicotine dependence, 406
- oxazepam, 603
- Oxford-GlaxoSmithKline (Ox-GSK) consortia, 417
- oxidative stress
 related to smoking, 421, 422
- oxycodone, 9, 551, 568
 formulations, 556
 formulations to prevent misuse, 572
 nonmedical use, 568, 569
 OxyContin, 9, 509, 541, 551, 568
 nonmedical use, 568
- pain management
 analgesic effects of opioid drugs, 554–555, 557–558
 distinguishing between opioid dependence and addiction, 578–579
 hyperalgesia induced by opioid drugs, 563
 opioid dependence and addiction in chronic-pain patients, 578–582
 opioid withdrawal syndrome in chronic-pain patients, 578
 use and misuse of prescription opioids, 546
- panic-spectrum disorder
 smoking and, 408
- paranoid personality disorder, 275
- paranoid psychosis
 stimulant drug-induced, 516–519
- parenting practices
 adolescent drug use and, 295–296
- partial agonist drug action, 108
- Pavlov, Ivan, 153, 218
- Pavlovian conditioning, 147
- peer pressure, 224, 246
- pentobarbital, 598, 599
- Percocet, 568
- Percodan, 551, 568
- personal accounts of drug addiction, 14–16
- personality disorders
 co-occurrence with SUDs, 53–54

- personality factors, 276
 genetic predisposition for SUDs, 177–180
 influence on initial drug use, 177–178
 influence on transition to SUDs, 178–179
 limitations of correlational studies, 179–180
 personality inventory
 questionnaires, 60
 personality research, 29, 276–277
 personality theory, 275–281
 Cloninger's tridimensional theory, 277–278
 drug-specific personality factors, 279–280
 impulsivity and SUD, 280–281
 McCrae and Costa five-factor theory, 277
 multiple-drug-use personality factors, 279–280
 negative emotionality and SUD, 280–281
 personality factors, 276
 personality traits, 275–276
 Tellegen's three-factor theory, 278–279
 personality traits, 275–276
 association with nicotine dependence, 411–412
 personality types and disorders
 addictive personality concept, 270–271
 antisocial personality disorder, 271–273
 avoidant personality disorder, 275
 borderline personality disorder, 271–272, 273–274
 categorical models, 271
 dimensional models, 271
 disorders associated with SUD, 271–275
 DSM-5 cluster B personality disorders, 271–272
 DSM-5 personality disorders, 270
 histrionic personality disorder, 274
 narcissistic personality disorder, 274–275
 paranoid personality disorder, 275
 personality concept, 148–149
 pharmaceutical drugs
 misuse of opioid drugs, 567–573
 nonmedical use of stimulants, 507–508
 opioid misuse “epidemic” in the United States, 546–548
 prevalence of stimulant use and use disorders, 492–493
 pharmacodynamic tolerance, 109–110, 130, 230
 pharmacodynamics, 106–110
 agonist drug action, 106–108
 alcohol, 313–317
 antagonist drug action, 106–108
 definition, 106
 definition of tolerance, 109
 direct drug interaction with receptors, 107–108
 dose effects of psychoactive drugs, 108
 drug binding with receptors, 107–108
 drug influence on neurotransmitter availability in the synapse, 107
 homeostatic processes in the CNS, 109
 inverse agonist drug action, 108
 mechanism of action of drugs, 106–108
 neuroadaptation and drug tolerance, 109–110
 partial agonist drug action, 108
 receptor density up- or down-regulation, 109–110
 role of autoreceptors, 109
 sensitization to drug effects, 109
 withdrawal syndrome, 110
 pharmacokinetics, 111–115
 alcohol, 311–313
 blood-brain barrier, 112–113
 definition, 106
 elimination of drugs from the body, 113–115
 factors affecting bioavailability of a drug, 111
 fat-sequestered drugs, 115
 first-pass effect, 114
 influence of strength and duration of drug effects, 114
 mechanism of the “euphoric rush”, 113
 metabolic tolerance, 113–114
 potential development of vaccines against drug effects, 113
 protein-binding of drugs in the bloodstream, 114–115
 routes of drug administration, 112
 withdrawal syndrome, 114
 phencyclidine, 107
 receptor binding, 108
 phenmetrazine, 487
 phenobarbital, 596, 599
 phenotypes, 192
 Phoenix, River, 576
 physician health program (PHP), 583–584
 physiological dependence
 DSM-5 meaning, 42
 physiological view of addiction, 10–11
 physiological withdrawal syndrome, 47–48
 pipe smoking, 420
 pleasurable effects of drugs
 neurological basis, 126–129
 subjective pleasure and positive reinforcement, 222–223
 polymorphisms, 192
 positive reinforcement, 219–225
 delay discounting, 222
 delay time and reinforcement strength, 221–222
 detection and measurement, 220–221
 direct and indirect sources of, 223–224
 intermittent reinforcement, 224–225
 neurological basis, 126–129

- positive reinforcement (*cont.*)
 neurological basis of
 positive reinforcement and
 pleasure, 126–129
 opioid drug use, 555–556,
 558–560
 power of alternative
 reinforcements, 224
 role in development of
 addiction, 125
 subjective pleasure and,
 222–223
 value of immediate rewards,
 221–222
- positron emission tomography
 (PET), 186–190
 imaging of the brain, 24
 use in diagnosis of SUDs, 61
- posttraumatic stress disorder
 (PTSD), 531
 co-occurrence with SUD,
 267–268
 in children, 296
 self-medication, 267–268
 smoking and, 408
- prefrontal cortex, 126, 127
 structures involved in
 compulsive drug-seeking,
 140–143
- pregnancy
 effects of fetal exposure to
 nicotine, 421
 effects of prenatal exposure
 to cocaine, 525–527
 effects of prenatal exposure
 to MDMA, 533
 effects of prenatal exposure
 to methamphetamine,
 525–527
 opioid drug use and neonatal
 abstinence syndrome,
 584–585
 risks of smoking during, 422
- prenatal exposure to drugs.
See pregnancy
- prescription opioids
 opioid misuse “epidemic”
 in the United States,
 546–548
 use and misuse of, 546,
 567–573
- prison
 Lexington prison/hospital
 opioid drug studies, 14–15
- process addictions, 10–11
- Profile of Mood States (POMS),
 17, 128, 147, 221, 454,
 528
- progesterone
 influence on stimulant drug
 effects, 501
- progression in addiction,
 85–87, 248–251
- protein binding of drugs in the
 bloodstream, 114–115
- Provigil, 489, 534
- Pryor, Richard, 503
- pseudoaddiction
 behaviors suggestive of,
 579–580
 opioid pain treatments and,
 578
- psychiatric disorders and SUD,
 269
 common factor model, 260,
 268–269
 co-occurrence, 53–54
 effects of smoking on
 psychiatric drug
 metabolism, 410–412
 genetic predisposition to
 both disorders, 268–269
 incidence of co-occurrence,
 257–258
 intensity of nicotine
 withdrawal symptoms,
 406–407
 models of interaction
 between, 258–269
 odds ratios for co-
 occurrence, 259
 prevalence of smoking
 tobacco, 406–410
 secondary psychopathology
 model, 260–261
 secondary SUD model, 260,
 261–268
 self-medication model, 260,
 261–268
 vignette (“Preparing for the
 Job Interview”), 257
- psychiatric evaluation, 60
- psychiatric syndromes
 related to heavy stimulant
 drug use, 516–519
- psychoactive drug use
 breadth and complexity of,
 5–6
 for consciousness-altering
 effects, 6–7
 for pleasurable effects, 6–7
 hazards of, 7–8
 incentives for, 6–7
 medical reasons for, 6–7
 public health and safety
 issues, 5–6
 utilitarian reasons for, 6–7
 variety of pathways into
 addiction, 217
- psychoactive drugs
 interactions with brain and
 body functions, 106
 interactions with
 neurotransmitters, 98–99
- psychoanalysis, 628
- psychoanalytic theory, 87, 88
- psychological stress
 genetically determined
 response, 184–185
 level of HPA axis activation,
 184–185
- psychological view of
 addiction, 10–11
- psychopathology
 genetic predisposition for
 SUDs, 177–180
 influence on initial drug use,
 177–178
 influence on transition to
 SUDs, 178–179
 limitations of correlational
 studies, 179–180
- psychopathology research, 29
- psychopharmacology
 behavioral tolerance,
 115–116
 nonpharmacological
 influences on drug effects,
 116–117
 pharmacodynamics, 106–110
 pharmacokinetics, 111–115
 research on pharmacological
 treatment of addiction, 117
 set and setting influences on
 drug effects, 116–117
 vignette (“I Want a New
 Drug”), 96–97
- psychosis
 risk related to cannabis use,
 475–476
- psychotherapy, 657–662
- public health and safety issues
 approach of the ICD system
 of the WHO, 49
 stimulant drug use, 519–520

- punding, 515–516
 Purple Haze (synthetic cannabinoid), 477
- quantitative trait loci (QTLs) studies with inbred mice, 205–206
- R.J. Reynolds Tobacco Company, 386
- Raistrick, Duncan, 364
- Rapid Alcohol Problems Screen (RAPSA), 57–58
- rating scales, 17
- Rational Recovery, 651
- rationalization defense mechanism, 87, 88, 234
- Reagan, Nancy
 Just Say No campaign, 442
- Reagan administration war on drugs, 442
- receptors
 autoreceptors, 105
 binding of neurotransmitters, 103
 cannabinoid receptors, 447–448, 556
 delta opioid receptors, 549
 density regulation in response to drugs, 109–110
 dopamine D2 receptor density and addiction, 133–134
 dopamine D2 receptor density and SUD risk, 187–190
 dopamine D4 receptors, 199
 drug binding with, 107–108
 excitatory effects, 104
 fast-acting receptors, 104
 GABA receptors, 200
 inhibitory effects, 104
 interactions with abused or addicting drugs, 104
 ionotropic actions, 104
 ionotropic receptors, 155
 kappa endorphin receptors, 104
 kappa opioid receptors, 549, 550
 metabotropic actions, 104
 metabotropic receptor activation and gene expression, 155
 mu endorphin receptors, 104
 mu opioid receptors, 549, 550, 553–554, 555
 neurotransmitter binding with postsynaptic receptors, 101
 nicotinic acetylcholine receptors, 395–396
 opioid receptors, 549
 role in drug tolerance development, 105
 serotonin 5HT2 receptors, 104
 slower-acting receptors, 104
 types and subtypes, 105
 variety of types and subtypes, 103–104
- recovery
 definition, 635
 nonabstinent recovery, 669–672
- Reding, Nick, 516–517, 519–520
- Reed, Lou, 610
- Reefer Madness* (film, 1936), 441
- reinforcement
 intermittent reinforcement, 224–225
 power of alternative reinforcements, 224
 promotion of nicotine addiction/dependence, 388–389
 reinforcing effects of addictive drugs, 125–129
 role in addictive behavior, 219
 role of dopamine, 99
See also negative reinforcement; positive reinforcement
- reinstatement (RI) model in animals, 152
- relapse
 abstinence violation effect, 668–669
 compensatory conditioning to drug-related stimuli, 148–149
 conditioned oppositional responses to drug-related stimuli, 148–149
 conditioned responses to drug-related stimuli, 147–149
- conditioned withdrawal response, 149
 definition, 668
 HALT (hunger, anger, loneliness, fatigue [tired]) risk factors, 149–150
 lingering vulnerability to, 144–152
 prevention, 668–669
 recurrence of drug-seeking in experimental animals, 145–146
 reinstatement (RI) model in animals, 145–146–147, 152
 risk factors for, 144–152
 risk of exposure to drug-related stimuli, 147–149
 risk related to long-term memory effects, 153–154
 risk with reexposure to the addictive drug, 146–147
 role of noradrenaline, 99
 role of the HPA axis, 151–152
 stress risk factor, 149–152
 use of craving to predict, 240
- religiosity
 expectations about effects of alcohol, 238
 influence on addictive drug use, 248
 spirituality of Alcoholics Anonymous, 645–647
- remission
 definition, 635
 factors promoting untreated remission, 643–644
 nonabstinent remission, 669–672
 untreated remission of SUD, 640–644
- Remoxy, 572
- Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), 326
- research
 specialized research areas related to SUDs, 28–29
 research methods, 14–26
 anecdotal accounts of drug addiction, 14–16
 animal models of addiction, 25–26

- brain structure and activity investigations, 22–24
 controlled experiments, 16–18
 electroencephalography (EEG), 24
 epidemiological surveys, 21–22
 ethical issues, 18
 fMRI of the brain, 24
 identifying the contribution of various risk factors, 20
 investigations of genetic vulnerability to SUDs, 25
 journals which report SUD research, 18
 Lexington prison/hospital opioid drug studies, 14–15
 limitations of direct observation, 14–16
 longitudinal studies, 19–20
 magnetic resonance imaging (MRI) of the brain, 23
 multivariate statistical analysis, 20, 22
 neuroimaging, 22–24
 personal accounts of drug addiction, 14–16
 PET imaging of the brain, 24
 quasi-experimental studies, 18–19
 rating scales, 17
 standardized instruments, 17
 systematic studies of addicted individuals, 18–19
 residential treatment programs, 654–655
 respondent conditioning, 218
 ReVia, 375, 552, 588
 reward
 delay discounting, 221–222
 reward circuitry in the brain, 126–129
 reward deficiency hypothesis, 134
 reward deficiency syndrome, 188
 reward deficiency theory, 199, 221
 reward value
 cannabis, 454–457
 nicotine, 423–424
 stimulant drugs, 498–499
 rimonabant, 316, 449, 454, 464
 risk factors for SUDs, 27–28, 251
 Ritalin, 9, 128, 487, 489, 493, 498, 534
 nonmedical use, 507–508
 Robinson, T.E., 220
 Rohypnol, 606–607
 Rolling Stones, 596
 routes of drug administration, 112
 Rush, Benjamin, 74, 75
 schizophrenia
 co-occurrence with SUD, 178
 genetic factors, 193
 schizophrenia patients
 effects of smoking on antipsychotic medication metabolism, 410–412
 prevalence of smoking, 409–410
 self-medication with addictive drugs, 262–263
 Schrieke, Ilse, 17
 Schuckit, Marc, 183–184, 227–228
 scopolamine, 103
 screening tests for SUDs, 37, 55–60
 accuracy of self-report tests, 59–60
 definition of screening, 56
 distinction from diagnostic testing, 56
 populations appropriate for screening, 56–57
 risk of false-positive and false-negative errors, 58–60
 sensitivity and specificity of tests, 58–60
 specific tests for special purposes, 57–58
 validity of screening tests, 58–60
 secobarbital, 599
 Seconal, 600
 secondary psychopathology model, 260–261
 secondary SUD model, 260, 261–268
 anxiety disorder, 264–267
 bipolar disorder, 262–263
 depression, 264–267
 emotional distress self-medication, 261–262
 nicotine dependence and psychiatric disorders, 263–264
 posttraumatic stress disorder (PTSD), 267–268
 schizophrenia, 262–263
 secrecy
 in addictive lifestyle, 11–13
 secular mutual assistance groups, 650–652
 Secular Organization for Sobriety (SOS), 651
 sedative-hypnotic drugs
 barbiturates, 598–601
 benzodiazepine receptor agonists (BZRAs), 596–597
 misuse of, 597–598
 types of anti-insomnia drugs, 595
 sedatives
 prevalence of use and SUDs, 8–9
 treatment of sedative use disorders, 617
 selective attention, 233
 self-awareness, 245
 self-efficacy, 233, 244
 self-medication
 explanation of SUDs, 179
 for nondrug problems, 180
 posttraumatic stress disorder (PTSD), 267–268
 self-medication model, 260, 261–268
 anxiety disorder, 264–267
 bipolar disorder, 262–263
 depression, 264–267
 emotional distress, 261–262
 nicotine dependence and psychiatric disorders, 263–264
 schizophrenia patients, 262–263
 sensitization, 154
 behavioral sensitization, 136–137
 compulsive drug-seeking and, 136–139
 incentive sensitization, 137–138, 147
 to drug effects, 109
 Serax, 603

- serotonin, 99–100, 103, 129
 effects of alcohol, 315
 role in mood disorders, 99
- serotonin receptors, 105
- sertraline, 596
- set and setting influences on
 drug effects, 116–117
- set-point.
 See hedonic set-point
- sexual activity
 aphrodisiac effect of
 stimulant drugs, 507
 effects of alcohol, 321–322
 effects of stimulant drugs,
 513–515
- sexual assault
 drug facilitated, 606–607
- Sheff, Nic, 11
- Shiffman, Saul, 668
- Siegel, Shepard, 230
- sildenafil, 515
- Silkworth, Robert, 645
- Silverstein, Shel, 463
- Simon, Paul, 456
- Sims, Zoot, 545
- single-nucleotide
 polymorphisms (SNPs),
 197, 203
- Skinner, B.F., 218
- Skinner box, 219
- Slovak, Hillel, 576
- SMART Recovery, 632, 645,
 651
- smoking.
 See nicotine addiction/
 dependence; tobacco use
- snuff, 385, 420
- social anxiety disorder, 275,
 408
- social cognition research, 29
- social influences on SUD,
 245–246
 modeling of behavior,
 245–246
- social learning theory, 232
- social media
 information on SUDs and
 treatment, 632–633
- Society for Neuroscience, 25
- socioeconomic status
 adolescent drug use and,
 296
- Sonata, 614
- Spice (synthetic cannabinoid),
 476–477
- sports
 use of performance-enhancing
 stimulant drugs, 497
- SSRI drugs, 596
- side effects, 601
- Stahl, Stephen, 140
- stereotyped behavior
 caused by heavy use of
 stimulant drugs, 515–516
- stimulant drug use
 acute effects, 496–503
 animal self-administration
 studies, 498–499
 behavioral effects, 496–498
 bioavailability, 493–494
 differences in individual
 responses, 501–502
 dosage effects, 496
 early twenty-first century,
 492–493
 effects of injecting or
 inhaling, 502–503
 effects on brain function,
 494–496
 effects on neurotransmitters,
 494–496
 euphoric “rush” followed
 by aversive dysphoria,
 502–503
 history of, 487–493
 hormonal influences on
 effects, 501
 incentive to escalate, 503
 influence of stress on effects,
 502
 medical uses, 489
 performance-enhancing
 effects, 496–497
 pharmacodynamics, 494–496
 pharmacokinetics, 493–494
 physiological effects,
 496–498
 prevalence of use and SUDs,
 8–9
 reasons for using, 487
 reward value of stimulant
 drugs, 498–499
 routes of administration, 493
 subjective effects, 499–500
 twentieth century, 488–492
 types of stimulant drugs, 487
 vignette (“The Pharmacist
 Dispenses Drugs”), 486
- stimulant use disorders,
 503–512
- addiction development and
 progression, 508–512
- antisocial behavior, 519–520
- cognitive behavioral therapy
 (CBT), 533
- cognitive impairment,
 520–522
- concurrent use of other
 addictive drugs, 509
- consequences of heavy use,
 512–527
- craving, 529–530
- dangers of inhalation and
 intravenous injection,
 510–512
- development of tolerance,
 509
- drug-induced paranoid
 psychosis, 516–519
- effects of prenatal exposure
 to stimulant drugs,
 525–527
- effects on sexual activity,
 513–515
- harm to organ systems
 and biological function,
 524–525
- Matrix Model approach to
 treatment, 533–534
- neurotoxicity, 522–524
- nonmedical use of
 pharmaceutical stimulants,
 507–508
- prevalence of addiction
 among users, 504–506
- psychiatric syndromes,
 516–519
- public health and safety
 issues, 519–520
- risk factors for problematic
 use, 506–507
- routes into addiction,
 508–509
- stereotyped behavior,
 515–516
- stimulant use binges,
 509–510
- toxic effects of stimulants,
 522–525
- treatment of addiction,
 533–535
- violence and child abuse
 associated with, 519–520
- withdrawal from heavy use,
 527–530

- stimulus control of SUD,
 228–232
 conditioned compensatory
 responses, 230–231
 conditioned responses to
 drug-related stimuli,
 228–229
 conditioned responses
 to subliminal stimuli,
 231–232
 context-dependent tolerance,
 230
 craving, 230–231
 stimulus-elicited responses,
 147–149
 Stop Signal Task, 284
 stratification
 confounding effect in gene
 studies, 197
 stress
 childhood stress and
 adolescent drug use,
 295–296
 genetically determined
 response to psychological
 stress, 184–185
 hormonal responses to, 151
 influence on effects of
 stimulant drugs, 502
 level of HPA axis activation,
 184–185
 prolonged national stress
 and SUD rates, 248
 risk factor for relapse,
 149–152
 role in vulnerability to
 addiction, 149
 stress responses to withdrawal
 influence in shifting the
 hedonic set-point, 134
 Stroop test, 284
 Structured Clinical Interview
 for DSM (SCID), 62
 Study of Addiction: Genetics
 and Environment (SAGE),
 204
 Sublimaze, 551–552
 nonmedical use, 568
 Suboxone, 552, 572, 587
 substance abuse
 DSM-IV definition, 10, 42
 DSM-IV diagnostic criteria,
 42–43
 meaning of the term, 36
 Substance Abuse and
 Mental Health Services
 Administration (SAMHSA),
 21
 Substance Abuse Subtle
 Screening Inventory
 (SASSI), 60
 substance dependence
 DSM-IV definition, 10, 42
 DSM-IV diagnostic criteria,
 42–43
 substance use disorders (SUDs)
 addictive lifestyle, 11–13
 biopsychosocial explanation,
 26–28
 definition of substance use
 disorder, 8
 diagnosis, 9–10
 DSM diagnostic criteria,
 9–10
 DSM-5 designations, 42
 essential features of, 38–41
 heterogeneity of, 52–54
 identification, 9–10
 identifying causes and
 consequences, 13–26
 physiological and
 psychological views, 10–11
 prevalence of, 8–9
 research methods, 14–26
 significance of a withdrawal
 syndrome, 10–11
 use of the term *substance use
 disorder*, 36
 Subutex, 552, 585, 587
 suicidal thinking
 nicotine addiction and, 409
 suicide
 risk related to alcohol use,
 327–328
 Susann, Jacqueline, 601
 synaptic microstructure
 changes caused by addictive
 drugs, 156–157
 synaptic plasticity, 157
 synaptic transmission, 101–103
 development of tolerance,
 103
 drug influence on
 neurotransmitter
 availability, 107
 neurotransmitter binding
 with postsynaptic
 receptors, 101
 neurotransmitter
 inactivation, 101–102
 neurotransmitter release into
 the synapse, 101
 neurotransmitter removal
 from the synapse, 102
 neurotransmitter re-uptake,
 102
 neurotransmitter synthesis,
 101
 receptor binding of
 neurotransmitters, 103
 regulatory processes, 103
 synthetic cannabinoids
 illicit use of, 476–477
 Synthetic Drug Abuse
 Prevention Act (2012), 477
 Szalavitz, Maia, 500, 649–650
 T-ACE test, 57
 Tellegen's three-factor theory
 of personality, 278–279
 tetrahydrocannabinol (THC),
 99, 101, 316
 content in cannabis,
 439–440
 fat-sequestration, 115
See also cannabis.
 thiamine
 deficiency in alcohol use
 disorders, 369–374
 thiorazine, 108
 Thorndike, Edward, 218
 Three Cs test (compulsion,
 control, consequences) for
 SUDs, 37–38, 390–391
 thresholds for identification
 of psychopathology,
 49–50
 Tiffany, Stephen, 240
 Tobacco and Genetics
 Consortium (TAG), 417
 tobacco use
 behavior of addictive
 tobacco use, 388–390
 biopsychosocial view, 390
 cancer risks, 421
 carcinogenic effects, 421
 cardiovascular disease
 associated with, 421–422
 changing attitudes over time,
 51, 247–248
 comparison with alcohol use
 disorders, 384–385

- concurrent use of other
 addictive drugs, 410–411
- consequences for
 adolescents, 415–416
- COPD associated with, 422
- cultural acceptance of, 384
- difficulty of stopping
 smoking, 403
- diseases caused by or related
 to, 421–422
- effects of passive exposure to
 tobacco smoke, 420–421
- effects on metabolism of
 antipsychotic medications,
 410–412
- factors in maintaining
 abstinence, 401–404
- genetics of smoking and
 nicotine dependence,
 417–419
- half-life of nicotine in the
 body, 395
- health risks of smoking in
 women, 385
- legality of, 384
- mechanisms of toxicity, 421
- medications to help smoking
 cessation, 430–431
- mortality associated with,
 383
- nicotine content of
 cigarettes, 394–395
- passive exposure to smoke
 (“second-hand smoke”),
 385
- premature deaths caused by,
 420
- prevalence in bipolar
 disorder, 409–410
- prevalence in different age
 groups, 383–384
- prevalence in people with
 anxiety disorders, 407–409
- prevalence in people with
 depression, 407–409
- prevalence in people with
 psychiatric disorders,
 406–410
- prevalence in schizophrenia
 patients, 409–410
- prevalence of different types
 of, 383–384
- prevalence of use and SUDs,
 8–9
- promotion by conditioning,
 389–390
- promotion by reinforcement,
 388–389
- risk in women who take oral
 contraceptives, 422
- risks during pregnancy, 422
- smoking in adolescents,
 414–417
- smoking in women, 412–413
- social acceptability, 384
- stopping smoking, 428–431
- synergistic toxic risk, 422
- tar in tobacco and tobacco
 smoke, 394
- toxic compounds in tobacco
 and tobacco smoke, 394
- toxic consequences, 386–387
- toxicity of nicotine, 394
- vignette (“Thinking about
 Stopping Smoking”),
 382–383
- weight gain on stopping
 smoking, 400
See also nicotine; nicotine
 addiction/dependence
- tobacco use in the United
 States
- chewing tobacco, 385
- cigarette smoking, 385–387
- continuing decline in
 prevalence, 387
- current smoking prevention
 initiatives, 387–388
- early twenty-first century,
 387–388
- educational level and, 387
- eighteenth and nineteenth
 centuries, 385
- electronic cigarettes, 387
- government attempts to
 reduce, 385–386
- growing awareness of the
 harms caused by smoking,
 385–387
- history of, 385–388
- snuff, 385
- socioeconomic status and, 387
- tobacco companies’
 awareness of tobacco
 toxicity, 386–387
- tobacco industry denial of
 the addictive nature of
 nicotine, 386–387
- twentieth century, 385–387
- tolerance, 130, 553
- alcohol, 319
- barbiturates, 601
- behavioral tolerance, 110,
 115–116
- conditioned tolerance, 116
- conditioned tolerance to
 opioid drugs, 561–562
- context-dependent tolerance,
 230
- context-specific effects,
 148–149
- definition of, 109
- development in MDMA,
 531–532
- development of nicotine
 tolerance, 395–396
- development with opioid
 drugs, 561–562
- development with stimulant
 drugs, 509
- difference between
 pleasurable and aversive
 drug effects, 134
- metabolic tolerance, 110,
 113–114
- neuroadaptation and,
 109–110
- pharmacodynamic tolerance,
 109–110, 130
- receptor density changes in
 response to drugs, 109–110
- role of receptors, 105
- role of synaptic regulatory
 processes, 103
- to the effects of THC in
 cannabis use, 449
- types of, 110
- Tour de France
 use of performance-
 enhancing stimulant
 drugs, 497
- toxicology tests
 diagnostic use, 61
- Tracy, Sarah, 74
- tranquillizer use disorders
 vignette (“Doctor Shopping
 for Xanax”), 594–595
- tranquillizers
 benzodiazepines, 596–597,
 601–612
- development of, 596–597
- misuse of, 597–598

- tranquilizers (*cont.*)
 prevalence of use and SUDs, 8–9
 types of anxiolytic drugs, 595
- transcription factors
 activation by addictive drugs, 155–156
 CREB (cAMP response element binding protein), 155–156
 delta FosB, 156
- transdermal route of entry for drugs, 112
- transgenic mice
 nicotinic Ach receptors, 396
- transition to SUDs
 influence of personality factors, 178–179
 influence of psychopathology, 178–179
- treatment of SUDs
 addiction as a treatable condition, 626–627
 Alcoholics Anonymous (AA) approach, 628–629
 cocaine addiction, 533–535
 cognitive behavioral therapy (CBT), 533
 current state of addiction treatment, 634
 differences among addicted individuals, 636–638
 effectiveness of treatment, 672–674
 evidence-based treatments, 634–635
 history of addiction treatment, 628–629
 information and support from the Internet and social media, 632–633
 many pathways out of SUD, 635
 Matrix Model, 533–534
 medical management of withdrawal, 638
 medical treatment for SUD, 638–639
 methamphetamine addiction, 533–535
 Minnesota Model, 629
 motivations for stopping versus continuing drug use, 635–636
- mutual assistance groups, 644–652
- nonabstinent remission and recovery, 669–672
- popular culture accounts of addiction treatment, 632
- prevalence of SUDs in the United States, 626
- proposed improvements, 674–675
- reasons for not seeking treatment, 640–644
- recovery, 635
- reluctance to accept help or stop using drugs, 627
- remission, 635
- similarities among addiction treatments, 636
- stimulant addiction, 533–535
- theory-based approaches, 627
- treatment philosophies, 627
- treatment types and levels of uptake, 626
- treatment-relevant features of SUDs, 635–640
- twenty-first-century approaches, 631–635
- untreated remission of SUD, 640–644
- use of medication as adjunct treatment, 635
- vignette (“The Almost-Invention”), 625–626
See also specific drugs
- treatment of SUDs by professionals, 652–669
- abstinence violation effect, 668–669
- agonist drug maintenance, 657
- brief intervention, 663
- cognitive behavioral therapy (CBT), 664–665
- counseling, 657–662
- couples therapy, 667
- dialectical behavior therapy (DBT), 666–667
- family therapy, 667–668
- group therapy, 659–660
- individual counseling and therapy, 660–661
- mindfulness training, 666
- Minnesota Model compared with mental health professional approaches, 629
- motivating abstinence, 661–662
- nonresidential treatment programs, 655–656
- office-based treatment, 652–653
- proposed improvements, 674–675
- psychotherapy, 657–662
- relapse prevention, 668–669
- residential treatment programs, 654–655
- treatment with co-occurring psychiatric disorders, 656–657
- twelve-step facilitation therapy, 665
- types of therapies used, 662–668
- typical features of SUD treatment programs, 656
- variations in diagnostic procedures, 653–654
See also specific drugs
- Trexan, 588
- triazolam, 603
- Tridimensional Personality Questionnaire (TPQ), 278
- Trotter, Thomas, 75
- Twain, Mark, 668
- TWEAK (tolerance, worried, eye-opener, amnesia) test, 57
- Tweak: Growing Up on Methamphetamines* (Sheff), 11
- tweaking, 515
- twelve-step facilitation therapy, 665
- twelve-step programs, 11, 147, 219, 629, 645
- character defects concept, 270
- disease concept of addiction, 78, 79
- evidence of effectiveness, 650
- informal diagnosis of SUDs, 37
- limited use of addiction treatment medications, 376

- managing cravings, 244
 mutual help approach, 628–629
 nicotine addiction and, 429–430
 online meetings, 632
 risk factors for relapse, 149–150
 role of narcissism in addiction, 274–275
 terminology used in, 36
 use of cognitive behavioral concepts, 234
See also Alcoholics Anonymous (AA)
- twin studies
 alcohol use disorders, 173–174
 genetic influence on SUDs, 172–175
 nicotine use and dependence, 174
 research approach, 172–173
 Twitter, 633
- University of Michigan, 21
 untreated remission of SUDs, 640–644
- vaccines against drug effects
 potential for addiction treatment, 534–535
 potential for development, 113
- Vaillant, George, 27, 79, 81–82, 83, 85, 343, 348, 351, 352, 356–357, 673
- Valium, 9, 262, 314, 596, 602, 603, 606, 608, 610
 protein binding in the bloodstream, 115
 withdrawal syndrome, 114
- vaping.
See electronic cigarettes
- varenicline, 244, 431, 534, 635
- ventral tegmental area
 role in SUDs, 126–129
- ventromedial prefrontal cortex, 142
- Versed, 603
- Viagra, 515
- Vicodin, 9, 509, 541, 551, 568
 nonmedical use, 568
- Viet Nam Era Twin Registry, 175
- Vietnam conflict
 heroin use among American military personnel, 545
- violence
 associated with stimulant drug use, 519–520
 Virginia Twin Registry, 175
 Vivitrol, 316, 375, 588
 Volkow, Nora, 128, 220
 Vyvanse, 489
- Wechsler Adult Intelligence Scale-IV, 473
- Wechsler Intelligence Scale for Children-Revised, 473
- weight gain on stopping smoking, 400, 413
- weight loss
 use of amphetamine for, 489
- Weil, Andrew, 450
- Wellbutrin, 431, 534
- Wernicke-Korsakoff syndrome, 364–365
- West, Robert, 27, 217, 299
- White, William, 86, 90
- whole-genome association tests, 203–204
- willpower, 140
- Wilson, Bill, 645
- Winehouse, Amy, 5, 627
- Wisconsin Inventory of Smoking Dependence Motives, 393–394
- withdrawal syndrome.
 alcohol, 317, 362–364
 barbiturates, 601
 benzodiazepine receptor agonists (BZRAs), 615–616
 benzodiazepines, 611–612
 cannabis, 464–465
 chronic-pain patients on opioid therapy, 578
 cocaine, 527–530
 compensatory response and, 230
 conditioned withdrawal response, 149, 566–567
delirium tremens stage of alcohol withdrawal, 363–364
 fat-sequestered drugs, 115
 mechanism of, 110
 medical management of withdrawal, 638
 methamphetamine, 527–530
 neonatal abstinence syndrome, 584–585
 neuroadaptation and, 109
- neurological substrates of acute and protracted withdrawal syndromes, 130–134
 nicotine, 174, 395–397, 399–406
 opioid drug addicts, 565–567
 opioid drugs, 562–563–564
 pharmacokinetics of drug elimination, 114
 physiological withdrawal syndrome, 47–48
 significance in defining addiction, 10–11
 stress responses influence the hedonic set-point, 134
 THC, 464–465
 withdrawal from heavy stimulant use, 527–530
 Z-drugs, 615–616
See also craving.
- women
 alcohol use disorders, 357–361
 cultural influences and vulnerabilities to alcohol use disorders, 359–360
 difficulty of detecting and diagnosing SUDs, 54
 factors in lower success in stopping smoking, 412–413
 fetal alcohol spectrum disorder, 372–374
 gender-related risk factors for alcohol use disorders, 359–360
 gender-specific differences in alcohol use disorders, 358–359
 health risks of smoking, 385
 hormonal factors in nicotine dependence, 413
 hormonal influences on effects of stimulant drugs, 501
 incidence of alcohol use disorders, 357
 patterns and consequences of disordered alcohol use, 361
 risk related to smoking and oral contraceptives, 422
 risks of smoking during pregnancy, 422
 sensitivity to MDMA, 530

- women (*cont.*)
 smoking in women, 412–413
 smoking-induced panic disorder, 408
 special features of alcohol use disorders, 357–361
 teratogenic effects of alcohol, 372–374
 use of alcohol compared with men, 357
 weight gain on stopping smoking, 413
 Women for Sobriety (WFS), 645, 652
 working memory
 cognitive demands of craving, 242
 World Health Organization (WHO), 308
- alcoholism as a disease, 75
 ICD system, 49
 Wurtzel, Elizabeth, 507
- Xanax, 48, 100, 108, 262, 333, 486, 509, 603, 606, 612
 vignette (“Doctor Shopping for Xanax”), 594–595
 withdrawal syndrome, 114, 115
- Yale University Center for Alcohol Studies, 74
 Young Adult Alcohol Problems Screening Test (YAAPST), 57
- Z-drugs, 596–597, 612–617
 abuse potential, 36
- adverse effects, 616–617
 bioavailability, 613–614
 effects on brain function, 614
 pharmacodynamics, 614
 pharmacokinetics, 613–614
 withdrawal syndrome, 615–616
 zaleplon, 614
See also Z-drugs
 Zofran, 356
 Zoloft, 596
 zolpidem, 598, 613, 614, 615–616–617
See also Z-drugs
 zopiclone, 613, 614, 615, 616–617
See also Z-drugs
 Zyban, 430–431